

11/03/00
JC891 U.S. PTO

Please type a plus sign (+) inside this box → +

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number


UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. ANG-1+3/CIP	Total Pages 106
First Named Inventor or Application Identifier Terence R. Jones et al			
Express Mail Label No.			

APPLICATION ELEMENTS <small>See MPEP Chapter 600 concerning utility patent application contents</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
---	--

<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form <small>(Submit an original, and a duplicate for fee processing)</small></p> <p>2. <input checked="" type="checkbox"/> Specification <small>(preferred arrangement set forth below)</small> [Total Pages 93] - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure</p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC d113) [Total Sheets 8]</p> <p>4. Oath or Declaration [Total Pages 2] a. <input checked="" type="checkbox"/> New Unexecuted (original) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 17 completed)</small> [Note Box 5 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(2) and 1.33(b).</small></p> <p>5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) <small>The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein</small></p>	<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identical of above copies</p>
--	--

ACCOMPANYING APPLICATION PARTS	
8. <input type="checkbox"/> Assignment Papers (cover sheet & Documents(s)) 9. <input type="checkbox"/> 37 CFR 3.27(B) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 14. <input type="checkbox"/> Small Entity Statement(s) <input checked="" type="checkbox"/> Statement filed in prior application Status still proper and desired 15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. <input type="checkbox"/> Other.

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information	
<input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP)	of prior application No: 09/285,783

18. CORRESPONDENCE ADDRESS	
<input type="checkbox"/> Customer Number or Bar Code Label  or <input checked="" type="checkbox"/> Correspondence address below <small>(Insert Customer No., or Attach bar code label here)</small>	
NAME	Shmuel Livnat Registration No. 33,949
ADDRESS	1233 20th Street, Suite 501, N.W.,
CITY	Washington
STATE	DC
ZIP CODE	20036
COUNTRY	United States of America
PHONE	(202) 955-3750
FAX	(202) 955-3751

Attorney Docket No. ANG-1+3/CIP
Date: November 3, 2000

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of
Inventor(s): Terence R. Jones, David N. HANEY and Janos VARGA
For: CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN
ACTIVATOR RECEPTOR

Enclosed are:

- ☒ Specification and Claim(s).
- ☒ Oath or Declaration (unexecuted).
- ☒ 8 sheet(s) of drawings.
- ☐ An assignment of the invention to _____
- ☐ Certified copy of _____ priority application(s).
- ☐ Associate Power of Attorney.

The fee has been calculated as shown below:

CLAIMS AS FILED				
FOR	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$355/\$710
TOTAL CLAIMS	52-20	32	X \$ 9 \$ 18	\$288.00
INDEP. CLAIMS	2-3	0	X\$ 40 \$ 80	\$ 0
Fee for Multiple Dependent Claims \$135/\$270				\$135.00
			TOTAL FILING FEE	\$778.00

- ☒ °Verified Statement claiming small entity status filed in parent application.

☐ Charge \$_____ to Deposit Account No. 18-0013 to cover the filing fee. A duplicate copy of this sheet is enclosed.

☐ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 or 1.17 which may be required during the entire pendency of this application, or to credit any overpayment, to Deposit Account No. 18-0013. A duplicate copy of this sheet is enclosed.

☒ No authorization to charge fees.

☐ A check in the amount of _____ to cover the filing fee is enclosed.


☐ Charge _____ to Deposit Account No. 18-0013 to cover the recordal fee. A duplicate copy of this sheet is enclosed.

☒ Applicant's undersigned attorney may be reached by telephone in our Washington D.C. Office at

(202) 955-3750.

All correspondence should be directed to our below listed address.

Date: November 3, 2000


Shmuel Livnat
Reg. No. 33,949

RADER, FISHMAN & GRAUER, P.L.L.C
1233 20th Street, NW, Suite 501
Washington, DC 20036
Telephone: (202) 955-3750
Facsimile: (202) 955-3751

CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR

BACKGROUND OF THE INVENTION

5 This application is a continuation-in-part of (1) USSN 09/285,783, filed 5 April 1999, which was a division of USSN 08/747,915, filed November 12, 1996 (issued as U.S. patent 5,942,492 on 24 August 1999) and (2) USSN 09/181,816, filed 29 October 1998. Both of the foregoing applications are incorporated by reference in their entirety.

Field of the Invention

10 The present invention relates to cyclic peptides that bind to the cell surface receptor (uPAR) for urokinase plasminogen activator (uPA) and, thus, are capable of delivering therapeutic agents or diagnostic probes to the surfaces of cells expressing this receptor. The invention also relates to pharmaceutical compositions comprising these peptides and their use to inhibit the binding of uPA to its cell surface receptor. By targeting therapeutic agents to uPAR or by inhibiting the binding of uPA to uPAR, it is possible to achieve a number of biological effects that include cell death, the inhibition of cell movement and migration and the inhibition of angiogenesis.

15 The peptides of the invention are capable of carrying a suitable detectable or imageable label so that they can be used to quantitate uPAR levels *in vitro* and *in vivo*. Such compositions are therefore useful as diagnostic, prognostic and imaging tools in all diseases and conditions where this receptor plays a pathological or otherwise undesirable role.

20 The peptides of the invention can also be immobilized to a suitable matrix and can be used for research applications to identify and isolate cells expressing uPAR and to identify and isolate uPAR from biological samples.

Description of the Background Art

25 The urokinase -type plasminogen activator (uPA) system is strongly linked to pathological processes, such as cell invasion and metastasis in cancer (Danø *et al.*, *Adv. Cancer Res.*, 44:139-266 (1985)). Cells produce uPA in an inactive form, pro-uPA or single-

chain uPA (scuPA), which then binds to its receptor, uPAR. This binding event is a prerequisite for the efficient activation of scuPA to two-chain uPA (tcuPA) in a cell milieu (Ellis *et al.*, *J. Biol. Chem.*, 264:2185-88 (1989)).

The amino acid sequence of the N-terminus of human pro-uPA [residues 1-44 of SEQ ID NO:1] is

```

      Ser Asn Glu Leu His Gln Val Pro Ser Asn Cys Asp Cys Leu Asn Gly
      1                                     10
      Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile His Trp Cys Asn Cys
      20                                     30
      Pro Lys Lys Phe Gly Gly Gln His Cys Glu Ile
      40
  
```

The structure of pro-uPA [SEQ ID NO:1] is shown in Figure 1.

uPA is a three-domain protein comprising (1) an N-terminal epidermal growth factor-like domain, (2) a kringle domain, and (3) a C-terminal serine protease domain. uPAR, the receptor for pro-uPA, is also a multi-domain protein anchored by a glycosylphosphatidylinositol anchor to the outer leaf of the cell membrane (Behrendt *et al.*, *Biol. Chem. Hoppe-Seyler*, 376:269-279 (1995)). The binding of uPA to uPAR initiates two separate events: the first, extracellular proteolysis, is mediated through the activation of plasminogen to plasmin, a broad-spectrum protease which can itself activate matrix metalloprotease (MMP) zymogens (Mazzieri *et al.*, *EMBO J.*, 16: 2319-32 (1997)), release latent growth factors such as TGF- β , IGF-I, and bFGF from their binding proteins or from their binding sites within the extracellular matrix (ECM) (Falcone *et al.*, *J. Biol. Chem.*, 268(16): 11951-11958 (1993); Lamarre *et al.*, *Biochem J.*, 302: 199-205 (1994); Remacle-Bonnet *et al.*, *Int. J. Cancer* 72:835-843 (1997)), and directly remodel certain ECM components such as fibronectin and vitronectin (Wachtfogel *et al.*, *J. Clin. Invest.*, 81:1310-1316 (1988); Sordat *et al.*, *Invasion Metastasis* 14: 223-33 (1994)).

The second series of events, triggered by uPA binding to uPAR depends upon transmembrane signal transduction and leads to the stimulation of cell differentiation and motility in several cell types, most notably endothelial cells, epithelial cells and leukocytes (Nusrat *et al.*, *Fibrinolysis* 6 (suppl 1):71-76 (1992); Fazioli *et al.*, *EMBO J.* 16: 7279-86

(1997); Schnaper *et al.*, *J. Cell. Physiol.* 165:107-118 (1994)). This second activity is independent of the proteolytic cascade described above. uPAR mediates these signaling events despite its lack of a transmembrane domain presumably through an adaptor protein(s) which couples extracellular binding to intracellular signaling cascades. The signaling mediated by uPAR probably involves multiple pathways, as with other cytokines. Jak/STAT and MAP-dependent pathways (which overlap with Jak/STAT) have been implicated (Koshelnick *et al.*, *J. Biol. Chem.* 272:28563-28567 (1997); Tang *et al.*, *J. Biol. Chem.* 273:18268-18272 (1998); Dumler *et al.*, *J. Biol. Chem.* 273:315-321 (1998)).

uPAR is not normally expressed at detectable levels on quiescent cells and must therefore be upregulated before it can initiate the activities of the uPA system. uPAR expression is stimulated *in vitro* by differentiating agents such as phorbol esters (Lund *et al.*, *J. Biol. Chem.* 266:5177-5181 (1991)), by the transformation of epithelial cells, and by various growth factors and cytokines such as VEGF, bFGF, HGF, IL-1, TNF α , (in endothelial cells) and GM-CSF (in macrophages) (Mignatti *et al.*, *J. Cell Biol.* 113:1193-1201 (1991); Mandriota *et al.*, *J. Biol. Chem.* 270:9709-9716; Yoshida *et al.*, *Inflammation* 20:319-326 (1996)). This up-regulation has the functional consequence of increasing cell motility, invasion, and adhesion (Mandriota *et al.*, *supra*). More importantly, uPAR appears to be up-regulated *in vivo* in most human carcinomas examined to date, specifically, in the tumor cells themselves, in tumor-associated endothelial cells undergoing angiogenesis and in macrophages (Pyke *et al.*, *Cancer Res.* 53:1911-15 (1993) which may participate in the induction of tumor angiogenesis (Lewis *et al.*, *J. Leukoc. Biol.* 57:747-751 (1995)). uPAR expression in cancer patients is present in advanced disease and has been correlated with a poor prognosis in numerous human carcinomas (Hofmann *et al.*, *Cancer* 78:487-92 (1996); Heiss *et al.*, *Nature Med.* 1:1035-39 (1995). Moreover, uPAR is not expressed uniformly throughout a tumor but tends to be associated with the invasive margin and is considered to represent a phenotypic marker of metastasis in human gastric cancer. The fact that uPAR expression is up-regulated only in pathological states involving ECM remodeling and cell motility such as cancer makes it an attractive marker for diagnosis as well as a selective target for therapy.

In order to design the peptides of the present invention, it was necessary first to identify the minimal binding epitope of uPA for uPAR. It had been shown earlier that the amino terminal fragment of uPA (residues 1-135) that lacked the serine protease domain, sufficed for high affinity (sub-nanomolar) binding. (Stoppelli *et al.*, *Proc. Natl. Acad. Sci. USA* 82:4939-43 (1985). Subsequent work showed that the growth factor domain alone (residues 1-48) conferred this binding. (Robbiati *et al.*, *Fibrinolysis*, 4:53-60 (1990); Stratton-Thomas *et al.*, *Protein Engineering* 8:463-470 (1995).)

Danø *et al.*, WO 90/12091 (18 October 1990), disclosed that the binding of uPA to uPAR could be prevented by administering a substance comprising a sequence identical or substantially identical to a uPAR binding site of uPA amino residues 12-32. Rosenberg *et al.*, WO 94/28145(9 December 1994) disclosed the preparation and use of non-fucosylated HuPA₁₋₄₈ that prevented uPA binding to uPAR.

Earlier studies with peptide fragments within the growth factor domain had shown that residues 20-30 conferred the specificity of binding, but that residues 13-19 were also needed if residues 20-30 were to attain the proper binding conformation. Specifically, the peptide [Ala¹⁹]uPA(12-32), which contains two cysteines (the third cysteine being replaced by Ala to avoid undesired disulfide bond formations) in its open chain form prevented uPA binding to uPAR with an IC₅₀ of 100 nM. In its oxidized cyclic form with an intrachain disulfide bond between Cys¹³ and Cys³¹, the peptide prevented uPA binding with an IC₅₀ of 40 nM. The authors proposed that residues 13-19 might act indirectly to provide a scaffold that would help residues 20-30 attain the correct binding conformation (Appella *et al.*, *J. Biol. Chem.*, 262:4437-4440 (1987).

These results were partially confirmed by Kobayashi *et al.* (*Int. J. Cancer*, 57:727-733 (1994)) who reported that, while the linear peptide 20-30 inhibited the binding of uPA to uPAR with an IC₅₀ of 1,000 nM, the longer peptide 17-34 was significantly more potent (IC₅₀ =100 nM). The corresponding longer peptide (17-34) derived from the mouse sequence inhibited spontaneous metastasis of Lewis Lung carcinoma in mice, whereas the corresponding linear shorter peptide (20-30) did not.

Most recently, Magdolen *et al.*, *Eur. J. Biochem.*, 237:743-751 (1996) reported results of alanine-scanning mutagenesis of the binding loop of the N-terminal uPA fragment and showed that the side chains of Asn22, Lys23, Tyr24, Phe25, Ile28 and Trp30 were important and should be preserved. These authors (citing Hansen *et al.*, *Biochemistry*, 33:4847-64 (1994)), disclosed that the region between Thr18 and Asn32 consisted of a flexible, seven-residue omega loop that is forced into a ring-like structure. In uPA, although Cys19 and Cys31 are in close proximity to each other (0.61 nm), they do not form a disulfide bond with each other. Instead Cys19 bonds with Cys 11, and Cys31 bonds with Cys 13. See Figure 2. Accordingly, the uPAR binding site of uPA does not form a simple, small ring structure.

In a related, commonly assigned patent application (USSN 08/747,915, incorporated herein by reference in its entirety) Jones *et al.* showed that novel cyclic molecules derived from the uPA peptide fragment 20-30 (in which residue 20 is covalently bonded to residue 30) bind to uPAR with IC₅₀ values in the 10-100 nM range.

Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.


SUMMARY OF THE INVENTION

The present inventors have discovered cyclic peptides that are useful as diagnostic and therapeutic agents. These peptides are based on the amino acid residues 20-30 (the receptor-binding region) of uPA. However, only six of the 11 amino acid residues in this region are essential for binding: Asn22, Lys23, Tyr24, Phe25, Ile28, and Trp30 (Magdolen *et al.*, *supra*). The other amino acid residues within the binding region were determined to be non-essential so the peptide can tolerate substitutions with minimal effects on its binding activity. The present inventors have substituted, at these non-essential positions, amino acid residues that may be conjugated to various therapeutic and diagnostic atoms or molecules. Such conjugates would home to sites of uPAR expression, which only occurs in pathological conditions such as cancer. The present inventors have devised linkers to cyclize the linear

peptide, providing for economical synthesis and resulting in cyclic peptides that are stable, soluble, bind avidly to uPAR and can serve as carriers of (i) detectable labels for diagnosis and (ii) therapeutic moieties for treatment of a variety of diseases in which uPAR is expressed on pathologic cells or that are treatable by inhibiting the binding of uPA to uPAR.

The therapeutic compositions of the present invention have the ability to (1) kill tumor cells expressing the receptor; (2) promote cell death and inhibit angiogenesis in tumor-associated endothelial cells expressing the receptor; (3) inhibit proteolytic cascades initiated by uPA; (4) inhibit uPA-dependent programmed gene expression; (5) inhibit cell motility, migration, and morphogenesis; (6) inhibit the activation of certain “pro” forms of growth factors to the active form; (7) inhibit angiogenesis; (8) inhibit tumor metastasis; (9) inhibit retinal neovascularization in the treatment of certain forms of blindness; (10) inhibit cell-mediated inflammatory response in diseases such as arthritis; (11) inhibit ischemia; (12) inhibit atheroma formation; and (13) inhibit neointima formation in the process of restenosis.

The present invention is directed to a cyclic peptide compound of the general formula:



wherein, all of X^1 through X^{11} represent D- or L-series amino acids (the binding region). The wild-type human amino acid sequence of X^1 through X^{11} is VSNKYFSNIHW [SEQ ID NO:2]. Various positions in X^1 through X^{11} may be substituted as follows (with the native human residue indicated first:

X^1 is Val, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X^2 is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X³ is Asn or Gln;

X⁴ is Lys, Arg or His;

X⁵ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhenylalanine
 (“HomoPhe”), β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)-
 alanine, or β -(2-naphthyl)alanine;

X⁶ is Phe, Tyr, Trp, substituted Phe, di-substituted Phe, HomoPhe, β -(3-
 pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-
 naphthyl)alanine;

X⁷ is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁸ is Asn, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁹ is Ile, Leu, Val, NorVal or NorLeu;

X¹⁰ is His, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X¹¹ is Trp, Tyr, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-
 pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-
 naphthyl)alanine.

“GluR¹” and “AspR¹” are substituted glutamic acid and aspartic acid, modified on their γ -
 and β -COOH groups, respectively, with an R group as described below. “L” or linker
 groups are described below. When X¹-X¹¹ is SEQ ID NO:2, then L is not L1 (see below).
 When X¹-X¹¹ does contain a Cys, HomoCys, Glu, Asp, GluR¹, or AspR¹, in the positions
 indicated above, then L is preferably L1. When linker L includes Cys, HomoCys, Glu, Asp,
 GluR¹ or AspR¹ within its structure, then X¹, X², X⁷, X⁸ and X¹⁰ preferably is not Cys,
 HomoCys, Glu, Asp, GluR¹ or AspR¹. L is a linking unit or linker, preferably creating a
 linear dimension between the C ^{α} carbon of amino acid X¹ and the C ^{α} carbon of amino acid
 X¹¹ of between about 5 and 10 Ångstrom units, or between about 6 and 8 Ångstrom units.

Reading in the direction X¹-L-X¹¹, L is preferably of one of the following fourteen
 basic types, designated L1 through L15:

L1 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CO-NH₂)-NH-

L2 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂SH)-CO-NH₂)-NH-

L3 -CO-CH(CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-

- L4 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂SH)-CO-NH₂)-NH-
 L5 -CO-CH(CH₂CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-
 L6 -CO-CH(CH₂CH₂COR¹)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-
 L7 -CO-CH(CH₂COR¹)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-
 5 L8 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂COR¹)-CO-NH₂)-NH-
 L9 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂COR¹)-CO-NH₂)-NH-
 L10 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-COR¹)-NH-
 L11 -CO-CH(CH₂CH₂COOH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-
 L12 -CO-CH(CH₂COOH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH-
 10 L13 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂COOH)-CO-NH₂)-NH-
 L14 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂COOH)-CO-NH₂)-NH-
 L15 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CO-NH-R¹)-NH-


The R¹ group in GluR¹, AspR¹ and in L6-L10 is may be a weakly basic diamino group -NH-R²-NH₂, where the pK_a of each of the primary amino groups in the parent diamine H₂N-R²-NH₂ is less than about 8.0 and where the pK_a of the primary amino group in -NH-R²-NH₂, when it is part R¹ is also less than about 8.0. Preferred examples of R² are *p*-phenylene, *o*-phenylene or *m*-phenylene.

For introducing the R¹ group into linker L15 that is part of cyclic peptide of this invention, a weakly basic amine R¹NH₂ is preferably bonded to the glycine “spur” (which is the underscored part of L15 shown above). Amines intended for this linker are amine are not specifically limited by structure. Rather, the only requirement is that the pK_a of its amino group be less than about 8.0. Aniline is a simple and prototypic example of a weakly basic amine, in fact, of the class of aromatic amines that are, in general, always weakly basic. To introduce an aromatic R¹ group, an aromatic amine is used. R¹ may be a homoaryl or a heteroaryl residue, and may be substituted with one or more substituents drawn from a broad range. The aromatic group may be polycyclic, wherein the various rings may be fused, unfused, or even both fused and unfused. In a polycyclic aromatic group, the rings may be homocyclic or heterocyclic, or even a mixture of both. The ring may be substituted with one


or more substituents drawn from a broad range. In a preferred embodiment R^1 in L15 is phenyl or substituted phenyl.

The R^1 group of L15 need not be an aromatic residue to have the requisite property of weak basicity. For example, the class of amines comprise any aromatic residue substituted with an ω -(aminooxy)_n-alkyl group of 1 to 10 carbons – this is described by the formula: $H_2N-O-(CH_2)_x-$ (where $x=1-10$). Another class of suitable amines are those having the formula $H_2N-CH_2-CO-NH-(CH_2)_x$ -homoaryl or $H_2N-CH_2-CO-NH-(CH_2)_x$ -heteroaryl, wherein $x=2-10$. The homoaryl or heteroaryl residue may be substituted with one or more substituents drawn from a broad range. As above, the homoaryl residue may be polycyclic, fused or unfused or both. The heteroaryl residue may additionally contain a homocyclic ring or more than one homocyclic rings that may be fused, unfused or even both fused and unfused. These compounds described above are non-limiting and are illustrative of the broad structural nature that can be the property of a weakly basic amine included within the scope of this invention.

A preferred group of compounds (shown with no substitutions to the native sequence in the 11 residue cyclic peptide corresponding to uPA20-30) that employ as linker L15 have the formula



In a preferred member of this group, designated Å36, R^1 is phenyl, and the formula of the compound is



Other preferred compounds related to Å36 have various substituted or alternative aromatic groups in place of the phenyl group.

Another preferred compound has the structure wherein $X^1 - X^{11}$ is SEQ ID NO:2, L is L10 and R^1 is (4-aminophenyl)amino.

5 It should be recognized that whenever a Cys, HomoCys, Glu, Asp, Glu R^1 or Asp R^1 amino acid residue is included in linker L, it may be either the D- or the L- enantiomer.

In the above compounds, any one of X^5 , X^6 or X^{11} may be mono- or di-substituted Phe, most preferably substituted with halo, a nitro or C1-C6 straight or branched chain alkyl.

10 The above compounds are characterized by an IC_{50} value in a competitive binding assay to uPAR *in vitro* of less than about 10^{-5} molar, preferably less than about 10^{-6} molar, most preferably less than about 10^{-7} molar.

Also provided is a uPAR-targeting pharmaceutical composition comprising an effective amount of the cyclic peptide compound as described above and a pharmaceutically acceptable carrier.

15 Another embodiment is a uPAR-targeting therapeutic composition comprising an effective amount of the cyclic peptide compound described above, to which is bound directly or indirectly a therapeutically active moiety; and a therapeutically acceptable carrier. A preferred therapeutic moiety is a radionuclide, examples of which are ^{125}I , ^{131}I , ^{90}Y , ^{67}Cu , ^{217}Bi , ^{211}At , ^{212}Pb , ^{47}Sc , and ^{109}Pd .

20 Preferably, the pharmaceutical or therapeutic compositions are in a form suitable for injection.

The compositions of the invention are used in methods and therapeutic compositions to inhibit the binding of uPA to uPAR and to target various therapeutic agents to tissues expressing uPAR, particularly in the treatment of cancer.

25 Thus, included here is a method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an

effective amount of any of the compositions described above. In a preferred embodiment, the method is used to inhibit the invasiveness of tumor cells.

The present invention also provides a method for treating a subject, preferably a human, having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to the subject an effective amount of a pharmaceutical or therapeutic composition as described above.

A nonlimiting list of diseases or conditions treatable as above is given below, and includes as a preferred embodiment, primary growth of solid tumors or leukemias and lymphomas, metastasis, invasion and/or growth of tumor metastases.

In another embodiment, this invention includes a diagnostically useful uPAR-targeting ligand composition which comprises a cyclic peptide compound described above that is diagnostically labeled, and a diagnostically acceptable carrier. Preferred detectable labels include a radionuclide, a PET-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a phosphorescer, a chemiluminescer or a bioluminescer. A most preferred radionuclide is selected from the group consisting of ^3H , ^{14}C , ^{35}S , ^{99}Tc , ^{123}I , ^{125}I , ^{131}I , ^{111}In , ^{97}Ru , ^{67}Ga , ^{68}Ga , ^{72}As , ^{89}Zr and ^{201}Tl .

In the diagnostic composition, the fluorescer or fluorogen is preferably fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, *o*-phthaldehyde, fluorescamine, a fluorescein derivative, Oregon Green, Rhodamine Green, Rhodol Green or Texas Red.

Also provided is a method for detecting the presence of uPAR (i) on the surface of a cell, (ii) in a tissue, (iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing uPAR due to a pathological state, comprising: (a) contacting the cell, tissue, organ or biological sample with the diagnostic composition above and (b) detecting the presence of the label associated with the cell, tissue, organ or sample.

In the above diagnostic method, the contacting may be *in vivo* and the detecting *in vitro*. In another embodiment, the contacting and the detecting are both accomplished *in vivo*.

This invention also includes an affinity ligand useful for binding to or isolating/enriching uPAR, comprising any of the above cyclic peptide compounds immobilized to a solid support or carrier. Such a ligand may be used to isolate uPAR from a complex mixture by (a) contacting the mixture with the affinity ligand; (b) allowing any uPAR to bind to the ligand; (c) removing unbound material from the ligand; and (d) eluting the bound uPAR, thereby isolating or enriching the uPAR.

Also provided is a method for isolating or enriching uPAR-expressing cells from a cell mixture, comprising: (a) contact the cell mixture with the uPAR-binding ligand compound as described above; (b) allowing any uPAR-expressing cell to bind to the compound; (c) separating cells bound to the ligand from unbound cells; and (d) removing the bound cells from the ligand (and optionally separating away the ligand), thereby isolating or enriching the uPAR-expressing cells. In a preferred embodiment such a method utilizes flow cytometric or “fluorescence-activated” cell sorting with a fluorescently labeled cyclic peptide compound.

Alternatively, uPAR-expressing cells are isolated from a cell mixture by (a) contacting the cell mixture with the above affinity ligand; (b) allowing any uPAR-expressing cell to bind to the ligand; (c) removing unbound cells from the ligand and from the bound cells; and (d) releasing the bound cells, thereby isolating or enriching the uPAR-expressing cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the pro-uPA molecule (SEQ ID NO:1]

Figure 2 shows the N-terminal growth factor domain of human uPA.

Figure 3 is a graph showing the binding of the three compounds of Example VI and the compound of Example VII to RKO human colon carcinoma cells. The peptide of Example VI in which $R^2 = p$ -phenylenediamine is termed “receptor targeting ligand- p -phenylenediamine derivative” (RTLPPD). When $R^2 = m$ -phenylenediamine, the resulting compound is termed RTLMPD. When $R^2 = o$ -phenylenediamine the resulting compound is termed RTLOPD. The compound of Example VII is Oregon Green-modified-RTLPPD.

Figure 4 is a graph showing the binding of a compound of Example VIII, biotin-modified-RTLPPD, to RKO human colon carcinoma cells.

Figure 5 is a graph showing the inhibition of PC-3 cell invasion by RTLPPD.

Figure 6 is a series of photomicrographs showing immunofluorescence detection of Oregon Green-modified-RTLPPD binding to stimulated endothelial cells. Top panels: phase micrographs; bottom panels: corresponding fluorescence micrographs.

Figure 7 is a graph showing the ability of Å36 to inhibit endothelial cells migration.

Figure 8 is a graph showing the inhibition by Å36 of invasiveness of prostate carcinoma cells (PC3MLN47) responding to hepatocyte growth factor (HGF) at 40 ng/mL).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present inventors have designed cyclic peptides capable of binding to uPAR, a receptor expressed in pathological conditions such as tumors, which peptides can be modified to incorporate therapeutic moieties without significant alteration in their binding properties. When linked to therapeutic moieties such as toxins and radioactive “warheads,” these peptides are used for selective delivery of these moieties to a tumor.

Since these peptides are also antagonists of uPA binding to uPAR, and inhibition of this interaction has been demonstrated to result in decreased metastasis, tumor growth, and angiogenesis, the present inventors conceived that a therapeutic conjugate comprising a uPAR-binding cyclic peptide and, for example, a radiotherapeutic would possess enhanced activity relative to either component alone. The potentiation of anti-angiogenic therapy with radiotherapy for suppressing tumor progression has recently been demonstrated (Mauceri *et al.*, *Nature* 394:287-91 (1998)). However, in that example, the radiotherapy was not targeted to the tumor but, rather, was administered systemically. A uPAR-targeted radiotherapeutic should have, at minimum, a similar anti-tumor effect, but with less systemic toxicity. The targeted approach described herein allows the administration of lower doses of systemic radioactivity while maintaining the same therapeutic effect, resulting in decreased non-specific exposure to radioactivity.

The present invention provides linkers that were designed to make the cyclic peptides water-soluble and easily synthesizable. Single functional groups were incorporated into the peptides for conjugating to a wide variety of therapeutically and diagnostically useful moieties. The peptides were designed so that modification of these functional groups does not introduce undesirable modifications in the binding region (residues in the peptide corresponding to Asn22, Lys23, Tyr24, Phe25, Ile28 and Trp30 of uPA).

Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹ residues have been substituted at single, non-essential amino acid position in the 11-mer sequence [SEQ ID NO:2] that comprises the "loop" of the cyclic peptide, specifically at positions 1, 2, 7, 8 and 10 (corresponding to 20, 21, 26, 27, and 29 of uPA). Each peptide has, at most, a single residue replaced by Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹. In addition, amino acid residues within the linker may also be replaced with Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹ leaving the 11 amino acids of the binding region intact as in native uPA. These series of peptides may be modified further using any thiol-selective (for Cys-containing peptides), carboxyl-selective (for Glu- and Asp-containing peptides) or amine-selective (for GluR¹- and AspR¹-containing peptides) reagent.

A weakly basic diamine may be introduced into the linker region via Glu or Asp in peptides containing linkers L11-L14 or into peptides containing Glu or Asp at non-essential positions within the binding region to produce a diamino group in the structure. Such diamines have been described above in connection with the linker groups. In general organic diamines are intended, and these are not limited by structure but only by the requirement that the pKa of each of the amino groups is less than about 8.0 even after coupling (as described above). The diamine (and resulting diamino group) may be symmetric or non-symmetric with respect to the placement of the amine groups upon the organic ring or chain. A phenylenediamine (ortho, meta or para), *infra*, is a simple example of a weakly basic diamine. However, the diamine is not necessarily cyclic but may be linear as well. For example a class of non-cyclic diamines are the α , ω -bis-(aminooxy)n-alkanes containing at least two and preferably no more than 10 carbon atoms. These are described by the formula $H_2N-O-(CH_2)_x-O-NH_2$ wherein $10 \geq x \geq 2$. Another class of suitable non-cyclic diamines


is exemplified by the formula $\text{NH}_2\text{CH}_2\text{CONH}(\text{CH}_2)_x\text{NHCOCH}_2\text{NH}_2$ wherein $10 \geq x \geq 2$. A diamine within the scope of this invention may be cyclic and if so, homocyclic heterocyclic, or polycyclic; it may be substituted with one or more substituents drawn from a broad range. If polycyclic, the various rings may be fused, unfused or even both; the rings may be

5 homocyclic, heterocyclic or a mixture of both; the rings may be substituted with one or more substituents drawn from a broad range. The amine groups may be direct substituents upon ring, spaced from the ring, or of both types.

Phenylenediamines are chosen as an example only, and when introduced into the linker region of a uPAR-targeting peptide of this invention, the phenylenediamine groups can

10 be modified at slightly acidic pH (6.5-7.0) by any amine-reactive reagent without the undesired side effect of modifying the critical Lys residue at position X^4 (corresponding to Lys23 in uPA) within the peptide. Peptides modified in this way retain binding activity to whole cells *e.g.*, tumor cells, endothelial cells, tumor tissue sections even after conjugation with Oregon Green (a fluorophore) or with biotin.

15 The preferred amino acid sequence and the preferred substitutions of the cyclic peptides are as follows:



wherein, all of X^1 through X^{11} represent D- or L-series amino acids (the binding region). The wild-type human amino acid sequence of X^1 through X^{11} in uPA is VSNKYFSNIHW [SEQ ID NO:2]. Various positions in X^1 through X^{11} may be substituted as follows :

20

X^1 is Val, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X² is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X³ is Asn or Gln;

X⁴ is Lys, Arg or His;

X⁵ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, homophenylalanine ("HomoPhe"), β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁶ is Phe, Tyr, Trp, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁷ is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁸ is Asn, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁹ is Ile, Leu, Val, NorVal or NorLeu;

X¹⁰ is His, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X¹¹ is Trp, Tyr, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine.

When X¹-X¹¹ is SEQ ID NO:2, then L is not L1.

When X¹-X¹¹ is substituted with one or more of Cys, HomoCys, Glu, Asp, GluR¹, or AspR¹, then L is preferably L1.

GluR¹ and AspR¹ are substituted glutamic acid and aspartic acid, modified on their γ - and β - COOH groups, respectively, with an R¹ group as described below.

The linker moiety L can be of the type designated L1-L15 above and forms a bridge between X¹¹ and X¹, thus cyclizing the peptide. When the linker L includes Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹ within its structure, they may be either the D- or L- enantiomers, and X¹, X², X⁷, X⁸ and X¹⁰ preferably are not modifiable residues such as Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹. In other words, preferably only one modifiable moiety is introduced into each peptide, whether in the X¹-X¹¹ sequence or within L. However, in other embodiments, uPAR-targeting cyclic peptides of this invention may include more than one, preferably two, modifiable amino acid sites to accommodate, for example, a cross-linking moiety in one position and a detectable label or a therapeutic moiety in the other.

Furthermore, as stated above, any one of X⁵, X⁶ or X¹¹ may be a substituted or disubstituted phenylalanine; the substituent may be a halo group, such as 4-fluoro, 4-chloro, 4-bromo, or 3,4-dichloro; a C1-C6 straight or branched chain alkyl; a nitro, or the like.

R¹ in GluR¹, AspR¹ and in linkers L6-L10 is -NH-R²-NH₂, such that the pK_a of each of the NH₂ groups in the parent diamine, H₂N-R²-NH₂, is less than about 8.0 and such that the pK_a of the primary amino group in -NH-R²-NH₂, when it is in GluR¹, AspR¹ or the linker, L, is also less than about 8.0. Preferred examples of the R² group are *p*-phenylene, *o*-phenylene or *m*-phenylene.

The present invention is also directed to the above peptides having an amino acid sequence corresponding to homologues of human uPA in other animal species. Several known animal sequences for residues corresponding to human uPA(20-30), the uPAR binding region, are:

Human	VS NKYFSNIHW	[SEQ ID NO:2]
Rat	VS YKYFSSIRR	[SEQ ID NO:3]
Mouse	VS YKYFSRIRR	[SEQ ID NO:4]
Pig	VS YKYFSNIQR	[SEQ ID NO:5]
Baboon	MS NKYFSSIHW	[SEQ ID NO:6]
Chicken	IT YRFFSQIKR	[SEQ ID NO:7]

uPA-uPAR interactions may exhibit varying degrees of species specificity. Thus, it is always preferred to use a cyclic peptide having the amino acid sequence (or a substitution variant thereof) of the species of the cells or animals being targeted or treated.

Based on the foregoing, preferred substituted peptides X¹-X¹¹ [SEQ ID NO:3] derived from rat uPA are:

X¹ is Val, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X² is Ser, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X³ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhe, β-(3-pyridyl)alanine, β-(2-thienyl)alanine, β-(1-naphthyl)alanine, or β-(2-naphthyl)alanine;

X⁴ is Lys, Arg or His;

X⁵ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhe, β-(3-pyridyl)alanine, β-(2-thienyl)alanine, β-(1-naphthyl)alanine, or β-(2-naphthyl)alanine;

X⁶ is Phe, Tyr, Trp, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁷ is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁸ is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁹ is Ile, Leu, Val, NorVal or NorLeu;

X¹⁰ is Arg, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, Lys, His or Ala;

X¹¹ is Arg, Lys or His.

Preferred substituted peptides X¹-X¹¹ [SEQ ID NO:4] derived from mouse uPA are:

X¹ is Val, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X² is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X³ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁴ is Lys, Arg or His;

X⁵ is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁶ is Phe, Tyr, Trp, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X⁷ is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X⁸ is Arg, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, Lys, His or Ala;

X⁹ is Ile, Leu, Val, NorVal or NorLeu;

X¹⁰ is Arg, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, Lys, His or Ala;

X¹¹ is Arg, Lys or His

It will be clear to one skilled in the art that similar substitutions can be made in the peptides corresponding to the uPAR binding fragment of uPA of other animal species in keeping with the teachings set forth above.

Cyclic Peptides

In the general formula, above, the amide bond (CO—NH) linking X¹ to X², is such that the carbonyl moiety is from amino acid X¹ and the amino moiety is from the amino acid X². The same is true for the link between X² and X³, and so on within the 11mer peptide.


The peptide has X¹ as its N-terminus and X¹¹ as its C-terminus.

To prepare a compound of Formula 1, L is chosen to provide, at one terminus, a functional group that can be chemically bonded to the carboxyl C atom of amino acid X¹¹

and, at the other terminus, a functional group that can be chemically bonded to the α -amino N atom of amino acid X^1 .

It is preferred that the linker L confer water solubility to the peptide and result in an intramolecular distance of 4-12 Å between the $C\alpha$ of the N-terminal residue X^1 and the $C\alpha$ of the C-terminal residue X^{11} .

Alternatively, the linear peptide $X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}$ can be synthesized with an extension at X^{11} comprising a portion of the ultimate final linker group L; that extension is termed L_b . After synthesis of the peptide chain, the X^1 terminus is extended with an extension that will also become part of the ultimate linker; this group is designated L_a . These steps yield a compound of the formula:



The free ends of L_a and L_b are then chemically bonded to each other. In this way, the linker L is formed during the cyclization step from pre-attached fragments L_a and L_b . In the examples given below for L, the direction of L, reading left to right, is from X^1 to X^{11} , *i.e.*, the C-terminus of L is bonded to X^1 , and the N-terminus of L is bonded to X^{11} .

When L includes a Cys, HomoCys, Glu, Asp, γ -carboxyl modified Glu or a β -carboxyl modified Asp residue, the configuration of the enantiomeric center of such a residue can be either L- or D-.

Cyclic peptides having a GluR¹ or AspR¹ residue within X¹-X¹¹

GluR¹ and AspR¹ may be incorporated directly into the peptides of the invention during synthesis. Glu and Asp in which the α -carboxyl group has been protected may be modified using any diamine $NH_2-R^2-NH_2$. The newly incorporated $-NH_2$ group is then blocked with a fluorenylmethyloxycarbonyl (Fmoc) group. Alternatively, the diamine $NH_2-R^2-NH_2$ may be blocked first to provide $NH_2-R^2-NH-Fmoc$ which is then coupled to the side chain carboxyl of the Asp or Glu in which the α -carboxyl group has been protected. Howsoever obtained, the modified amino acid is incorporated into the cyclic peptides of the invention using standard peptide synthetic techniques as described below.

Cyclic Peptides having an L6, L7, L8, L9 or L10-type Linker

To prepare the compounds having a linker L of the L6, L7, L8, L9 or L10 type, the L is chosen to provide, at one terminus, a functional group that can be chemically bonded to the carboxyl C atom of amino acid X¹¹ and, at the other terminus, a functional group that can be chemically bonded to the α -amino N atom of amino acid X¹.

It is preferred that linker L confer water solubility to the peptide and result in an interatomic distance of 4-12 Å between the C α of the N-terminal residue X¹ and the C α of the C-terminal residue X¹¹.

The R¹-group may be introduced into the linker L in two different ways (see below):

(a) as part of the peptide synthesis on the resin, or;

(b) by making a peptide intermediate with a linker L containing COOH in lieu of COR¹, which intermediate is subsequently modified to incorporate the R¹ group.

General Chemical Synthetic Procedures

The peptides of the invention are preferably prepared using solid-phase synthesis, such as that generally described by Merrifield, *J. Amer. Chem. Soc.*, 85:2149-54 (1963), although other equivalent chemical syntheses known in the art are also useful. Solid-phase peptide synthesis may be initiated from the C-terminus of the peptide by coupling a protected α -amino acid to a suitable resin. Such a starting material can be prepared by attaching an α -amino-protected amino acid by an ester linkage to a chloromethylated resin or to a hydroxymethyl resin, or by an amide bond to a BHA resin or MBHA resin.

The preparation of the hydroxymethyl resin is described by Bodansky *et al.*, *Chem. Ind.*, 38:1597-1598 (1966). Chloromethylated resins are commercially available from BioRad Laboratories, Richmond, Calif. and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart *et al.* ("Solid Phase Peptide Synthesis," Freeman & Co., San Francisco 1969, chapter 1, 1-6). BHA and MBHA resin supports are commercially available and are generally used only when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus.

The amino acids X¹ through X¹¹ can be coupled to the growing peptide chain using techniques well known in the art for the formation of peptide bonds. For example, one method involves converting the amino acid to a derivative that will render the carboxyl group

of the amino acid more susceptible to reaction with the free N-terminal amino group of the growing peptide chain. Specifically, the C-terminal of the protected amino acid can be converted to a mixed anhydride by the reaction of the C-terminal with ethyl chloroformate, phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate, or pivaloyl chloride or the like acid chlorides. Alternatively, the C-terminal of the amino acid can be converted to an active ester, such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a *p*-nitrophenyl ester, a N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole.

Another coupling method involves the use of a suitable coupling agent, such as N,N'-dicyclohexylcarbodiimide or N,N'-diisopropylcarbodiimide. Other appropriate coupling agents, apparent to those skilled in the art, are disclosed in Gross *et al.*, *The Peptides: Analysis, Structure, Biology, Vol. I*, "Major Methods of Peptide Bond Formation," Academic Press, 1979, the disclosure of which is hereby incorporated by reference.

It will be recognized that the α -amino group of each amino acid employed in the peptide synthesis must be protected during the coupling reaction to prevent side reactions involving their active α -amino function. It should also be recognized that certain amino acids contain reactive side-chain functional groups (e.g., sulfhydryl, amino, carboxyl, and hydroxyl) and that such functional groups must also be protected with suitable protecting groups to prevent a chemical reaction from occurring at either (1) the α -amino group site or (2) a reactive side chain site during both the initial and subsequent coupling steps.

In the selection of a particular protecting group to be used in synthesizing the peptides, the following general rules are typically followed. Specifically, an α -amino protecting group (a) should render the α -amino function inert under the conditions employed in the coupling reaction, (b) should be readily removable after the coupling reaction under conditions that will not remove side-chain protecting groups and will not alter the structure of the peptide fragment, and (c) should substantially reduce the possibility of racemization upon activation, immediately prior to coupling.

On the other hand, a side-chain protecting group (a) should render the side chain functional group inert under the conditions employed in the coupling reaction, (b) should be

stable under the conditions employed in removing the α -amino protecting group, and (c) should be readily removable from the desired fully-assembled peptide under reaction conditions that will not alter the structure of the peptide chain.

It will be apparent to those skilled in the art that the protecting groups known to be useful for peptide synthesis will vary in reactivity with the agents employed for their removal. For example, certain protecting groups, such as triphenylmethyl and 2-(p-biphenyl)isopropylloxycarbonyl, are very labile and can be cleaved under mild acid conditions. Other protecting groups, such as t-butyloxycarbonyl (BOC), t-amylloxycarbonyl, adamantyl-oxycarbonyl, and p-methoxybenzyloxycarbonyl, are less labile and require moderately strong acids for their removal, such as trifluoroacetic, hydrochloric, or boron trifluoride in acetic acid. Still other protecting groups, such as benzyloxycarbonyl (CBZ or Z), halobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl cycloalkyloxycarbonyl, and isopropylloxycarbonyl, are even less labile and require even stronger acids, such as hydrogen fluoride, hydrogen bromide, or boron trifluoroacetate in trifluoroacetic acid, for their removal. Suitable protecting groups, known in the art are described in Gross *et al.*, *The Peptides: Analysis, Structure, Biology, Vol. 3*: "Protection of Functional Groups in Peptide Synthesis," Academic Press, 1981.

Preferred classes of amino acid protecting groups useful for protecting the α -amino group or for protecting a side chain group are described below.

(1) For an α -amino group, three typical classes of protecting groups are: (a) aromatic urethane-type protecting groups, such as fluorenylmethyloxycarbonyl (Fmoc), CBZ, and substituted CBZ, such as, *e.g.*, p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, and p-methoxybenzyloxycarbonyl, o-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 2,6-dichlorobenzyloxycarbonyl, and the like; (b) aliphatic urethane-type protecting groups, such as BOC, t-amylloxycarbonyl, isopropylloxycarbonyl, 2-(p-biphenyl)-isopropylloxycarbonyl, allyloxycarbonyl and the like; and (c) cycloalkyl urethane-type protecting groups, such as cyclopentylloxycarbonyl, adamantylloxycarbonyl, and cyclohexylloxycarbonyl. The preferred α -amino protecting groups are BOC and Fmoc.

(2) For the ϵ -amino group of Lys, protection is attained using any of the groups mentioned above in (1) such as BOC, FMOC, 2-chlorobenzyloxycarbonyl and the like.

(3) For the guanidino group of Arg, protection is attained by nitro, tosyl, CBZ, adamantyloxycarbonyl, 2,2,5,7,8-pentamethylchroman-6-sulfonyl, 2,3,6-trimethyl-4-methoxyphenylsulfonyl, or BOC groups.

(4) For the hydroxyl group of Ser, Thr, or Tyr, protection may be attained by *t*-butyl; benzyl (BZL); or substituted BZL, such as *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-chlorobenzyl, *o*-chlorobenzyl, and 2,6-dichlorobenzyl.

(5) For the carboxyl group of Asp or Glu, protection is attained by esterification using such groups as BZL, *t*-butyl, cyclohexyl, cyclopentyl, and the like. The fluorenylmethyl group can also be also usefully employed.

(6) For the imidazole nitrogen of His, the benzyloxymethyl (BOM), the tosyl, or the 2,4-dinitrophenyl group is suitably employed as a protecting group.

(7) For the phenolic hydroxyl group of Tyr, a protecting group such as tetrahydropyranyl, *tert*-butyl, trityl, BZL, chlorobenzyl, 4-bromobenzyl, and 2,6-dichlorobenzyl is employed, most preferably bromobenzyloxycarbonyl.

(8) For the amino groups of Asn or Gln, xanthyl (Xan) is preferably employed.

(9) The amino acid Met is preferably left unprotected.

(10) For the thio group of Cys, *p*-methoxybenzyl can be employed. The acetamidomethyl (Acm) can also be also usefully employed.

(11) For the thio group of HomoCys, *p*-methoxybenzyl can be employed. The acetamidomethyl (Acm) can also be also usefully employed.

The first C-terminal amino acid of the growing peptide chain, *e.g.*, Lys, is typically protected at the N-amino position by an appropriately selected protecting group such as BOC. The BOC-Lys-(2-chlorobenzyloxycarbonyl)-OH group can be first coupled to a benzylhydramine resin using isopropylcarbodiimide at about 25°C for two hours with stirring or to a chloromethylated resin according to the procedure set forth in Horiki *et al.*, *Chemistry Letters*, 165-168 (1978). Following the coupling of the BOC-protected amino acid to the resin support, the α -amino protecting group is usually removed, typically by using

trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The α -amino group de-protection reaction can occur over a wide range of temperatures, but is usually carried out at a temperature between about 0°C and room temperature.

Other standard α -amino group de-protecting reagents, such as HCl in dioxane, and conditions for the removal of specific α -amino protecting groups are well-known in the art, *e.g.*, Lübke *et al.*, *Chemie und Biochemie der Aminosäuren, Peptide und Proteine I*, Chapter II-1, 102-117 (Georg Thieme Verlag Stuttgart 1975), which is hereby incorporated by reference in its entirety. Following the removal of the α -amino protecting group, the unprotected α -amino group (with any side-chain still protected), can be coupled in a stepwise manner in the intended sequence.

An alternative to the stepwise approach is the fragment condensation method in which pre-formed peptides of shorter length, each representing part of the desired sequence, are coupled to a growing chain of amino acids bound to a solid phase support. For this stepwise approach, a particularly suitable coupling reagent is N,N'-dicyclohexyl-carbodiimide or diisopropylcarbodiimide. The selection of the coupling reagent, as well as the choice of the fragmentation pattern needed to couple fragments of the desired nature and size are important for success and are known to those skilled in the art.

Each protected amino acid or peptide is usually introduced into the solid-phase reactor in amounts in excess of stoichiometric quantities, and the coupling is carried out in an organic solvent, such as dimethylformamide (DMF), CH₂Cl₂ or mixtures thereof. If incomplete coupling occurs, the coupling procedure is customarily repeated before removal of the α -amino protecting group in preparation for coupling to the next amino acid. Following the removal of the α -amino protecting group, the remaining α -amino-protected and side-chain-protected amino acids can be coupled in a stepwise manner in the intended sequence. The success of the coupling reaction at each stage of the synthesis may be monitored. A preferred method of monitoring the synthesis is by the ninhydrin reaction (Kaiser *et al.*, *Anal. Biochem.*, 34:595 (1970)). The coupling reactions can also be performed automatically using well-known commercial methods and devices, for example, a Beckman 990 Peptide Synthesizer.

After it has been synthesized, the protected peptide must be cleaved from the resin support, and all protecting groups must be removed. The cleavage reaction and removal of the protecting groups are suitably accomplished concomitantly or consecutively with de-protection reactions. When the peptide is anchored to the resin by an ester bond, it can be
 5 cleaved by any reagent that is capable of breaking an ester linkage and of penetrating the resin matrix. One especially useful method is by treatment with liquid anhydrous hydrogen fluoride. This reagent will usually cleave not only the peptide from the resin, but will also remove all acid-labile protecting groups and, thus, will result in a fully de-protected peptide. When additional acid-stable protecting groups are present, additional de-protection steps
 10 must be carried out, either before or after the hydrogen fluoride treatment described above, according to specific needs and circumstances.

When a chloromethylated resin is used, the hydrogen fluoride cleavage/de-protection treatment generally results in the formation of the free peptide acids. When a benzhydrylamine resin is used, the hydrogen fluoride treatment generally results in free
 15 peptide amides. Reaction with hydrogen fluoride in the presence of anisole and dimethylsulfide at 0° C for one hour will typically remove the side-chain protecting groups and, concomitantly, release the peptide from the resin.

In appropriate circumstances and when certain structural requirements of the peptide are met, when it is desired to cleave the peptide without removing protecting groups, the protected peptide-resin can be subjected to methanolysis, thus yielding a protected peptide
 20 with a methylated C-terminal carboxyl group. This methyl ester can be hydrolyzed under mild alkaline conditions to give the free carboxyl group. Protecting groups on the peptide chain can then be removed by treatment with a strong acid, such as liquid hydrogen fluoride. A particularly useful technique for methanolysis is that of Moore *et al.*, in *Peptides, Proc. Fifth Amer. Pept. Symp.*, 518-521 (Goodman *et al.*, eds., 1977), which calls for treating the
 25 protected peptide-resin with methanol and potassium cyanide in the presence of a crown ether.

Other methods for cleaving a protected peptide from chloromethylated resins include (1) ammonolysis and (2) hydrazinolysis. If desired, the resulting C-terminal amide or

hydrazide can be hydrolyzed to the free C-terminal carboxyl moiety, and the protecting groups can be removed conventionally. The protecting group present on the N-terminal α -amino group may be removed either before or after cleaving the protected peptide from the support.

Purification of the cyclic peptides of the invention is typically achieved using chromatographic techniques, such as preparative HPLC (including reverse phase HPLC), and other forms of chromatography including gel permeation, ion exchange, partition and affinity. Preferred affinity matrices comprise antibodies, preferably monoclonal antibodies). Other purification approaches include conventional techniques such as countercurrent distribution and the like.

Incorporation of R¹ groups into Peptides containing Glu or Asp

The R¹ group may be incorporated into the peptides of the invention after synthesis and purification of the peptides. Peptides containing Glu or Asp in X¹-X¹¹ or peptides containing linkers L11-L14 may be modified by reaction with HR¹, where R¹ is -NH-R²-NH₂. HR¹ is preferably a phenylenediamine and may be incorporated via the γ - or β - carboxyl side chains of Glu and Asp, respectively, using a water soluble carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).

Peptidomimetics

A preferred type of chemical derivative of the peptides described herein is a peptidomimetic compound which mimics the biological effects of the Compositions. A peptidomimetic agent may be an unnatural peptide or a non-peptide agent which recreates the stereospatial properties of the binding elements of the Compositions such that it has the binding activity or biological activity of the Compositions. Similar to the cyclic peptides of the Compositions, a peptidomimetic will have a binding face (which interacts with uPAR) and a non-binding face. Again, similar to the cyclic peptides of the Compositions, the non-binding face of a peptidomimetic will contain functional groups which can be modified by various therapeutic and diagnostic moieties without modifying the binding face of the peptidomimetic. A preferred embodiment of a peptidomimetic would contain an aniline on

the non-binding face of the molecule. The NH₂-group of an aniline has a pK_a ~ 4.5 and could therefore be modified by any NH₂ - selective reagent without modifying any NH₂ functional groups on the binding face of the peptidomimetic. Other peptidomimetics may not have any NH₂ functional groups on their binding face and therefore, any NH₂, without regard for pK_a could be displayed on the non-binding face as a site for conjugation. In addition other modifiable functional groups, such as -SH and -COOH could be incorporated into the non-binding face of a peptidomimetic as a site of conjugation. A therapeutic or diagnostic moiety could also be directly incorporated during the synthesis of a peptidomimetic and preferentially be displayed on the non-binding face of the molecule.

This invention also includes compounds which retain partial peptide characteristics. For example, any proteolytically unstable bond within a cyclic peptide of the invention could be selectively replaced by a non-peptidic element such as an isostere (N-methylation; D-amino acid at the S₁ site) or a reduced peptide bond while the rest of the molecule retains its peptide nature.

Peptidomimetic compounds, either agonists, substrates or inhibitors, have been described for a number of bioactive peptides such as opioid peptides, VIP, thrombin, HIV protease, *etc.* Methods for designing and preparing peptidomimetic compounds are known in the art (Hruby, V.J., *Biopolymers* 33:1073-1082 (1993); Wiley, R.A. *et al.*, *Med. Res. Rev.* 13:327-384 (1993); Moore *et al.*, *Adv. in Pharmacol* 33:91-141 (1995); Giannis *et al.*, *Adv. in Drug Res.* 29:1-78 (1997), which references are incorporated by reference in their entirety). These methods are used to make peptidomimetics that possess at least the binding capacity and specificity of the cyclic peptides and preferably also possess the biological activity. Knowledge of peptide chemistry and general organic chemistry available to those skilled in the art are sufficient, in view of the present disclosure, for designing and synthesizing such compounds.

For example, such peptidomimetics may be identified by inspection of the crystallographically-derived three-dimensional structure of a peptide of the invention either free or bound in complex with uPAR. Alternatively, the structure of a peptide of the invention bound to uPAR can be gained by the techniques of nuclear magnetic resonance

spectroscopy. The better knowledge of the stereochemistry of the interaction of a cyclic peptide with its receptor will permit the rational design of such peptidomimetic agents.

All the foregoing peptides, as well as their variants and chemical derivatives, including peptidomimetics, must bind to human uPAR with an $IC_{50} \leq 10 \mu M$. This activity is characterized in greater detail below.

In Vitro Testing of Compositions

A. Assay for ligand binding to uPAR on whole cells

The uPAR-targeting ligand compounds of the invention are readily tested for their binding to uPAR, preferably by measuring their ability to inhibit the binding of [125 I]DFP-uPA to uPAR in a competitive ligand-binding assay. The assay may employ whole cells that express uPAR, for example cells lines such as RKO or HeLa. A preferred assay is conducted as follows. Cells (about 5×10^4 /well) are plated in medium (*e.g.*, MEM with Earle's salts/10% FBS + antibiotics) in 24-well plates, then incubated in a humid 5% CO₂ atmosphere until the cells reach 70% confluence. Catalytically inactivated high molecular weight uPA (DFP-uPA) is radioiodinated using Iodo-gen[®] (Pierce) to a specific activity of about 250,000 cpm/mg. The cell-containing plates are then chilled on ice and the cells are washed twice (5 minutes each) with cold PBS/ 0.05% Tween-80. Test compounds are serially diluted in cold PBS/ 0.1 % BSA/ 0.01% Tween-80 and added to each well to a final volume of 0.3mL 10 minutes prior to the addition of the [125 I]DFP-uPA. Each well then receives 9500 cpm of [125 I]DFP-uPA at a final concentration of 0.2 nM). The plates are then incubated at 4°C for 2 hrs, after which time the cells are washed 3x (5 minutes each) with cold PBS/ 0.05% Tween-80. NaOH (1N) is added to each well in 0.5 mL to lyse the cells, and the plate is incubated for 5 minutes at room temperature or until all the cells in each well are lysed as determined by microscopic examination. The contents of each well are then aspirated and the total counts in each well determined using a gamma counter. Each compound is tested in triplicate and the results are expressed as a percentage of the total radioactivity measured in wells containing [125 I]DFP-uPA alone, which is taken to represent maximum (100 %) binding.

The inhibition of binding of [125 I]DFP-uPA to uPAR is usually dose-related, such that the concentration of the test compound necessary to produce a 50% inhibition of binding (the IC_{50} value), which is expected to fall in the linear part of the curve, is easily determined. In general, the compounds of the invention have IC_{50} values of less than about 10^{-5} M.

- 5 Preferably, the compounds of the invention have IC_{50} values of less than about 10^{-6} M and, even more preferably, less than about 10^{-7} M.

B. Assay for the invasion of PC-3 cells

The ability of PC-3 (human prostatic carcinoma) cells to invade through a reconstituted basement membrane (Matrigel®) is measured using transwell tissue culture inserts. Invasive cells are defined as cells which are able to traverse through the Matrigel® and upper aspect of a polycarbonate membrane and adhere to the bottom of the membrane. Transwells (Costar) containing polycarbonate membranes (8.0 μ m pore size) are coated with Matrigel® (Collaborative Research), which has been diluted in sterile PBS to a final concentration of 75 μ g/mL (60 μ L of diluted Matrigel® per insert), and placed in the wells of a 24-well plate. The membranes are dried overnight in a biological safety cabinet, then rehydrated by adding 100 μ L of DMEM containing antibiotics for 1 hour on a shaker table. The DMEM is removed from each insert by aspiration and 0.8 mL of DMEM/10 % FBS/antibiotics is added to each well of the 24-well plate such that it surrounds the outside of the transwell ("lower chamber"). Fresh DMEM/ antibiotics (100 μ L), human Glu- plasminogen (5 μ g/mL), and any inhibitors to be tested are added to the top, inside of the transwell ("upper chamber"). The tumor cells which are to be tested are trypsinized and resuspended in DMEM/antibiotics, then added to the top chamber of the transwell at a final concentration of 800,000 cells/mL. The final volume of the upper chamber is adjusted to 200 μ L. The assembled plate is then incubated in a humid 5% CO₂ atmosphere for 72 hours. After incubation, the cells are fixed and stained using DiffQuik® (Giemsa stain) and the upper chamber is then scraped using a cotton swab to remove the Matrigel® and any cells which did not invade through the membrane. The membranes are detached from the transwell using an X-acto® blade, mounted on slides using Permount® and cover-slips, then counted

under a high-powered (400x) field. An average of the cells invaded is determined from 5-10 fields counted and plotted as a function of inhibitor concentration.

C. Assay for endothelial cell migration

Transwells (Costar, 8.0 μm pore size; for additional description, see Tumor Cell Invasion Methods) are coated with type I collagen (50 $\mu\text{g/mL}$) by adding 200 μL of the collagen solution per transwell, then incubating overnight at 37°C. The transwells are assembled in a 24-well plate and a chemoattractant (*e.g.*, FGF-2) is added to the bottom chamber in a total volume of 0.8 mL media. Endothelial cells, such as human umbilical vein endothelial cells (HUVEC), which have been detached from monolayer culture using trypsin, are diluted to a final concentration of 1×10^6 cells/mL with serum-free media and 0.2 mL of this cell suspension is added to the upper chamber of each transwell. Inhibitors to be tested are added to both the upper and lower chambers, and the migration is allowed to proceed for 5hrs in a humidified atmosphere at 37°C. The transwells are removed from the plate stained using DiffQuik®. Cells which did not migrate are removed from the upper chamber by scraping with a cotton swab and the membranes are detached, mounted on slides, and counted under a high-power field (400x) to determine the number of cells migrated.

D. Assays for cell proliferation/cytotoxicity

The anti-proliferative and cytotoxic effects of the compositions may be determined for various cell types including tumor cells, endothelial cells, fibroblast, and macrophages. This is especially useful when testing a compound of the invention which has been conjugated to a therapeutic moiety such as a radiotherapeutic or a toxin. For example, a conjugate of one of the compositions with Bolton-Hunter reagent which has been iodinated with ^{131}I would be expected to inhibit the proliferation of cells expressing uPAR (most likely by inducing apoptosis). These assays are also useful for estimating toxic effects against normal cells, which do not express uPAR. Anti-proliferative effects would be expected against tumor cells and stimulated endothelial cells but not quiescent endothelial cells (see Figure 6) or normal human dermal fibroblasts, neither of which express uPAR. Any anti-

proliferative or cytotoxic effects observed in the normal cells would represent non-specific toxicity of the conjugate.

A typical assay would involve plating cells at a density of 5-10,000 cells per well in a 96-well plate. The conjugate to be tested is added at a concentration 10x the IC₅₀ measured in a binding assay (this will vary depending on the conjugate) and allowed to incubate with the cells for 30 minutes. The cells are washed 3X with media, then fresh media containing [³H]thymidine (1 µCi/mL) is added to the cells and they are allowed to incubate at 37°C in 5% CO₂ for 24 and 48 hours. Cells are lysed at the various time points using 1 M NaOH and counts per well determined using a β-counter. Proliferation may be measured non-radioactively using MTS reagent or CyQuant[®] to measure total cell number. For cytotoxicity assays (measuring cell lysis), a Promega 96-well cytotoxicity kit is used. If there is evidence of anti-proliferative activity, induction of apoptosis may be measured using TumorTACS (Genzyme).

In Vivo Study of the uPAR-Targeted Cyclic Peptides

A. Corneal Angiogenesis Model

The protocol used is essentially identical to that described by Volpert *et al.* (*J. Clin. Invest.* 98:671-679 (1996)). Briefly, female Fischer rats (120-140 gms) are anesthetized and pellets (5 µl) comprised of Hydron[®], bFGF (150 nM), and the compounds to be tested are implanted into tiny incisions made in the cornea 1.0-1.5 mm from the limbus.

Neovascularization is assessed at 5 and 7 days after implantation. On day 7, animals are anesthetized and infused with a dye such as colloidal carbon to stain the vessels. The animals are then euthanized, the corneas fixed with formalin, and the corneas flattened and photographed to assess the degree of neovascularization. Neovessels may be quantitated by imaging the total vessel area or length or simply by counting vessels.

B. Matrigel[®] Plug Assay

This assay is performed essentially as described by Passaniti *et al.* (*Lab Invest.* 67:519-528 (1992)). Matrigel[®] is maintained at 4°C until use. Just prior to injection, Matrigel[®] is mixed with angiogenic factors (100 ng/mL bFGF, 100 ng/mL VEGF), then

injected s.c. into mice (0.5 mL per mouse). The injected Matrigel® forms a palpable solid gel which persists for 10 days, at which time the animals are euthanized. The Matrigel® plugs are removed and angiogenesis quantitated by measuring the amount of hemoglobin in the Matrigel® plugs or by counting neovessels in sections prepared from the plugs. Anti-CD31 staining may be used to confirm neovessel formation and microvessel density in the plugs.

C. Chick chorioallantoic membrane (CAM) angiogenesis assay

This assay is performed essentially as described by Nguyen et al (*Microvascular Res.* 47:31-40 (1994)). A mesh containing either angiogenic factors (bFGF) or tumor cells plus inhibitors is placed onto the CAM of an 8-day old chick embryo and the CAM observed for 3-9 days after implantation of the sample. Angiogenesis is quantitated by determining the percentage of squares in the mesh which contain blood vessels.

D. Xenograft model of subcutaneous (s.c.) tumor growth

Nude mice are inoculated with MDA-MB-231 cells (human breast carcinoma) and Matrigel® (1 x 10⁶ cells in 0.2mL) s.c. in the right flank of the animals. The tumors are staged to 200 mm³ and then treatment with a test composition is initiated (100µg/animal/day given q.d. IP). Tumor volumes are obtained every other day and the animals are sacrificed after 2 weeks of treatment. The tumors are excised, weighed and paraffin embedded. Histological sections of the tumors are analyzed by H and E, anti-CD31, Ki-67, TUNEL, and CD68 staining.

E. Xenograft Model of Metastasis

The compounds of this invention are also tested for inhibition of late metastasis using an experimental metastasis model (Crowley, C.W. *et al.*, *Proc. Natl. Acad. Sci. USA* 90 5021-5025 (1993)). Late metastasis involves the steps of attachment and extravasation of tumor cells, local invasion, seeding, proliferation and angiogenesis. Human prostatic carcinoma cells (PC-3) transfected with a reporter gene, preferably the green fluorescent protein (GFP) gene, but as an alternative with a gene encoding the enzymes chloramphenicol acetyltransferase (CAT), luciferase or LacZ, are inoculated into nude mice. This permits

utilization of either of these markers (fluorescence detection of GFP or histochemical colorimetric detection of enzymatic activity) to follow the fate of these cells. Cells are injected, preferably iv, and metastases identified after about 14 days, particularly in the lungs but also in regional lymph nodes, femurs and brain. This mimics the organ tropism of naturally occurring metastases in human prostate cancer. For example, GFP-expressing PC-3 cells (1×10^6 cells per mouse) are injected iv into the tail veins of nude (*nu/nu*) mice. Animals are treated with a test composition at 100µg/animal/day given q.d. IP. Single metastatic cells and foci are visualized and quantitated by fluorescence microscopy or light microscopic histochemistry or by grinding the tissue and quantitative colorimetric assay of the detectable label.

For a compound to be useful in accordance with this invention, it should demonstrate activity in at least one of the above (*in vitro* or *in vivo*) assay systems.

Diagnostic and Prognostic Compositions

The cyclic peptides of the invention have been designed so that they can be detectably labeled and used, for example, to detect a peptide binding site or receptor (such as uPAR) on the surface or in the interior of a cell. The fate of the peptide during and after binding can be followed *in vitro* or *in vivo* by using the appropriate method to detect the label. The labeled peptide may be utilized *in vivo* for diagnosis and prognosis, for example to image occult metastatic foci or for other types of *in situ* evaluations.

Suitable detectable labels include radioactive, fluorescent, fluorogenic, chromogenic, or other chemical labels. Useful radiolabels, which are detected simply by gamma counter, scintillation counter or autoradiography include ^3H , ^{125}I , ^{131}I , ^{35}S and ^{14}C . In addition, ^{131}I is a useful therapeutic isotope (see below).

Common fluorescent labels include fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, *o*-phthaldehyde and fluorescamine. The fluorophore, such as the dansyl group, must be excited by light of a particular wavelength to fluoresce. See, for example, Haugland, *Handbook of Fluorescent Probes and Research Chemicals*, Sixth Ed., Molecular Probes, Eugene, OR., 1996). Fluorescein, fluorescein derivatives and fluorescein-

like molecules such as Oregon GreenTM and its derivatives, Rhodamine GreenTM and Rhodol GreenTM, are coupled to amine groups using the isothiocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups. Similarly, fluorophores may also be coupled to thiols using maleimide, iodoacetamide, and aziridine-reactive groups. The long wavelength rhodamines, which are basically Rhodamine GreenTM derivatives with substituents on the nitrogens, are among the most photostable fluorescent labeling reagents known. Their spectra are not affected by changes in pH between 4 and 10, an important advantage over the fluoresceins for many biological applications. This group includes the tetramethylrhodamines, X-rhodamines and Texas RedTM derivatives. Other preferred fluorophores for derivatizing the peptide according to this invention are those which are excited by ultraviolet light. Examples include cascade blue, coumarin derivatives, naphthalenes (of which dansyl chloride is a member), pyrenes and pyridyloxazole derivatives. Also included as labels are two related inorganic materials that have recently been described: semiconductor nanocrystals, comprising, for example, cadmium sulfate (Bruchez, M. *et al.*, *Science* 281:2013-2016 (1998), and quantum dots, *e.g.*, zinc-sulfide-capped cadmium selenide (Chan, W.C.W. *et al.*, *Science* 281:2016-2018 (1998)).

In yet another approach, the amino group of a cyclic uPAR-targeting peptide is allowed to react with reagents that yield fluorescent products, for example, fluorescamine, dialdehydes such as *o*-phthaldialdehyde, naphthalene-2,3-dicarboxylate and anthracene-2,3-dicarboxylate. 7-nitrobenz-2-oxa-1,3-diazole (NBD) derivatives, both chloride and fluoride, are useful to modify amines to yield fluorescent products.

The peptides of the invention can also be labeled for detection using fluorescence-emitting metals such as ¹⁵²Eu, or others of the lanthanide series. These metals can be attached to the peptide using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA, see Example X, *infra*) or ethylenediaminetetraacetic acid (EDTA). DTPA, for example, is available as the anhydride, which can readily modify the NH₂-containing uPAR-targeting peptides of this invention.

For *in vivo* diagnosis or therapy, radionuclides may be bound to the cyclic peptide either directly or indirectly using a chelating agent such as DTPA and EDTA. Examples of such radionuclides are ^{99}Tc , ^{123}I , ^{125}I , ^{131}I , ^{111}In , ^{97}Ru , ^{67}Cu , ^{67}Ga , ^{68}Ga , ^{72}As , ^{89}Zr , ^{90}Y and ^{201}Tl . Generally, the amount of labeled peptide needed for detectability in diagnostic use will vary depending on considerations such as age, condition, sex, and extent of disease in the patient, contraindications, if any, and other variables, and is to be adjusted by the individual physician or diagnostician. Dosage can vary from 0.01 mg/kg to 100 mg/kg.

The cyclic peptides can also be made detectable by coupling them to a phosphorescent or a chemiluminescent compound. The presence of the chemiluminescent-tagged peptide is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescers are luminol, isoluminol, thionin acridinium ester, imidazole, acridinium salt and oxalate ester. Likewise, a bioluminescent compound may be used to label the peptides. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

In yet another embodiment, colorimetric detection is used, based on chromogenic compounds which have, or result in, chromophores with high extinction coefficients.

In situ detection of the labeled peptide may be accomplished by removing a histological specimen from a subject and examining it by microscopy under appropriate conditions to detect the label. Those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

The term "diagnostically labeled" means that the peptide has attached to it a diagnostically detectable label. There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include radioactive isotopes, paramagnetic isotopes, and compounds

which can be imaged by positron emission tomography (PET). Those of ordinary skill in the art will know of other suitable labels for binding to the peptides used in the invention, or will be able to ascertain such, by routine experimentation.

For diagnostic *in vivo* radioimaging, the type of detection instrument available is a major factor in selecting a radionuclide. The radionuclide chosen must have a type of decay which is detectable by a particular instrument. In general, any conventional method for visualizing diagnostic imaging can be utilized in accordance with this invention. Another factor in selecting a radionuclide for *in vivo* diagnosis is that its half-life be long enough so that the label is still detectable at the time of maximum uptake by the target tissue, but short enough so that deleterious irradiation of the host is minimized. In one preferred embodiment, a radionuclide used for *in vivo* imaging does not emit particles, but produces a large number of photons in a 140-200 keV range, which may be readily detected by conventional gamma cameras.

In vivo imaging may be used to detect occult metastases which are not observable by other methods. The expression of uPAR correlates with progression of diseases in cancer patients such that patients with late stage cancer have higher levels of uPAR in both their primary tumors and metastases. uPAR-targeted imaging could be used to stage tumors non-invasively or to detect other diseases which are associated with the presence of increased levels of uPAR (for example, restenosis that occurs following angioplasty).

Reagent Compositions

In another embodiment, the peptides or derivatives of the present invention are used as affinity ligands for binding to uPAR in assays, preparative affinity chromatography and solid phase separation of uPAR. Such compositions may also be used to identify, enrich, purify or isolate cells to which the peptide or derivative binds, preferably through a specific receptor-ligand interaction using flow cytometric and/or solid phase methodologies. The peptide or derivative is immobilized using conventional methods, *e.g.* binding to CNBr-activated Sepharose® or Agarose®, NHS-Agarose® or Sepharose®, epoxy-activated Sepharose® or Agarose®, EAH-Sepharose® or Agarose®, streptavidin-Sepharose® or

Agarose[®] in conjunction with biotinylated peptide or derivatives. In general the peptides or derivatives of the invention may be immobilized by any other method which is capable of immobilizing these compounds to a solid phase for the indicated purposes. See, for example *Affinity Chromatography: Principles and Methods (Pharmacia LKB Biotechnology)*. Thus, one embodiment is a composition comprising any of the peptides, derivatives or peptidomimetics described herein, bound to a solid support or a resin. The compound may be bound directly or via a spacer, preferably an aliphatic chain having about 2-12 carbon atoms.

By “solid phase” or “solid support” or “carrier” is intended any support or carrier capable of binding the peptide or derivative. Well-known supports, or carriers, in addition to Sepharose[®] or Agarose[®] described above are glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses such as nitrocellulose, polyacrylamides, polyvinylidene difluoride, other agaroses, and magnetite, including magnetic beads.. The carrier can be totally insoluble or partially soluble. The support material may have any possible structural configuration so long as the coupled molecule is capable of binding to receptor material. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube or microplate well, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, bottom surface of a microplate well, *etc.*

The compositions of the present invention may be used in diagnostic, prognostic or research procedures in conjunction with any appropriate cell, tissue, organ or biological sample of the desired animal species. By the term “biological sample” is intended any fluid or other material derived from the body of a normal or diseased subject, such as blood, serum, plasma, lymph, urine, saliva, tears, cerebrospinal fluid, milk, amniotic fluid, bile, ascites fluid, pus and the like. Also included within the meaning of this term is a organ or tissue extract and a culture fluid in which any cells or tissue preparation from the subject has been incubated.

Pharmaceutical and Therapeutic Compositions and Their Administration

The compounds that may be employed in the pharmaceutical compositions of the invention include all of those compounds described above, as well as the pharmaceutically acceptable salts of these compounds. Pharmaceutically acceptable acid addition salts of the compounds of the invention containing a basic group are formed where appropriate with strong or moderately strong, non-toxic, organic or inorganic acids by methods known to the art. Exemplary of the acid addition salts that are included in this invention are maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate and nitrate salts.

Pharmaceutically acceptable base addition salts of compounds of the invention containing an acidic group are prepared by known methods from organic and inorganic bases and include, for example, nontoxic alkali metal and alkaline earth bases, such as calcium, sodium, potassium and ammonium hydroxide; and nontoxic organic bases such as triethylamine, butylamine, piperazine, and tri(hydroxymethyl)methylamine.

As stated above, the compounds of the invention possess the ability to inhibit invasiveness or angiogenesis, properties that are exploited in the treatment of cancer, in particular metastatic cancer. A composition of this invention may be active *per se*, or may act as a "pro-drug" that is converted *in vivo* to the active form.

The compounds of the invention, as well as the pharmaceutically acceptable salts thereof, may be incorporated into convenient dosage forms, such as capsules, impregnated wafers, tablets or injectable preparations. Solid or liquid pharmaceutically acceptable carriers may be employed.

Preferably, the compounds of the invention are administered systemically, *e.g.*, by injection. When used, injection may be by any known route, preferably intravenous, subcutaneous, intramuscular, intracranial or intraperitoneal. Injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like. Similarly, the

carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (*e.g.*, a solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension. A summary of such pharmaceutical compositions may be found, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton Pennsylvania (Gennaro 18th ed. 1990).

The pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral, parenteral, topical, transdermal, intravaginal, intrapenile, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration. The pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.

The present invention may be used in the diagnosis or treatment of any of a number of animal genera and species, and are equally applicable in the practice of human or veterinary medicine. Thus, the pharmaceutical compositions can be used to treat domestic and commercial animals, including birds and more preferably mammals, as well as humans.

Though the preferred routes of administration are systemic the pharmaceutical composition may be administered topically or transdermally, *e.g.*, as an ointment, cream or gel; orally; rectally; *e.g.*, as a suppository, parenterally, by injection or continuously by infusion; intravaginally; intrapenilely; intranasally; intrabronchially; intracranially, intraaurally; or intraocularly.

For topical application, the compound may be incorporated into topically applied vehicles such as a salve or ointment. The carrier for the active ingredient may be either in sprayable or nonsprayable form. Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water. Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like.

If desired, these may be sterilized or mixed with auxiliary agents, *e.g.*, preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like. Preferred vehicles for non-sprayable topical preparations include ointment bases, *e.g.*, polyethylene glycol-1000 (PEG-1000); conventional creams such as HEB cream; gels; as well as petroleum jelly and the like.

Also suitable for topical application are sprayable aerosol preparations wherein the compound, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant. The aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the compounds of the invention.

For the preferred topical applications, especially for humans, it is preferred to administer an effective amount of the compound to an infected area, *e.g.*, skin surface, mucous membrane, eyes, *etc.* This amount will generally range from about 0.001 mg to about 1 g per application, depending upon the area to be treated, the severity of the symptoms, and the nature of the topical vehicle employed.

Therapeutic compositions of the invention may comprise, in addition to the modified cyclic peptide, one or more additional anti-tumor agents, such as mitotic inhibitors, *e.g.*, vinblastine; alkylating agents, *e.g.*, cyclophosphamide; folate inhibitors, *e.g.*, methotrexate, piritrexim or trimetrexate; antimetabolites, *e.g.*, 5-fluorouracil and cytosine arabinoside; intercalating antibiotics, *e.g.*, adriamycin and bleomycin; enzymes or enzyme inhibitors, *e.g.*, asparaginase, topoisomerase inhibitors such as etoposide; or biological response modifiers, *e.g.*, interferons or interleukins. In fact, pharmaceutical compositions comprising any known cancer therapeutic in combination with the cyclic peptides disclosed herein are within the scope of this invention. The pharmaceutical composition may also comprise one or more other medicaments to treat additional symptoms for which the target patients are at risk, for example, anti-infectives including antibacterial, anti-fungal, anti-parasitic, anti-viral, and anti-coccidial agents.

Other Therapeutic Compositions

In another embodiment, the compounds of this invention are “therapeutically conjugated” and used to deliver a therapeutic agent to the site to which the compounds home and bind, such as sites of tumor metastasis or foci of infection/inflammation. The term “therapeutically conjugated” means that the modified cyclic peptide or peptidomimetic is conjugated to another therapeutic agent that is directed either to the underlying cause or to a “component” of tumor invasion, angiogenesis or inflammation.

Examples of therapeutic radioisotopes useful herein include ^{125}I , ^{131}I , ^{90}Y , ^{67}Cu , ^{217}Bi , ^{211}At , ^{212}Pb , ^{47}Sc , and ^{109}Pd . These atoms can be conjugated to the peptide compounds directly, indirectly as part of a chelate (see Example X), or, in the case of iodine, indirectly as part of an iodinated Bolton-Hunter group. The radioiodine can be introduced either before or after this group is coupled to the peptide compound (see Example IX, below).

Preferred doses of the radionuclide conjugates are a function of the specific radioactivity to be delivered to the target site which varies with tumor type, tumor location and vascularization, kinetics and biodistribution of the cyclic peptide carrier, energy of radioactive emission by the nuclide, *etc.* Those skilled in the art of radiotherapy can readily adjust the dose of the cyclic peptide in conjunction with the dose of the particular nuclide to effect the desired therapeutic benefit without undue experimentation. For example, an effective dose of ^{131}I -RTLPPD is between about 1 and 1000 Ci per gram of tumor for an extracranial tumor.

Another therapeutic approach included here is the use of boron neutron capture therapy, where a boronated cyclic peptide is delivered to a desired target site, such as a tumor, most preferably an intracranial tumor (Barth, R.F., *Cancer Invest.* 14:534-550 (1996); Mishima, Y. (ed.), *Cancer Neutron Capture Therapy*, New York: Plenum Publishing Corp., 1996; Soloway, A.H., *et al.*, (eds), *J. Neuro-Oncol.* 33:1-188 (1997). The stable isotope ^{10}B is irradiated with low energy (<0.025eV) thermal neutrons, and the resulting nuclear capture yields α -particles and ^7Li nuclei which have high linear energy transfer and respective path lengths of about 9 and 5 μm . This method is predicated on ^{10}B accumulation in the tumor with lower levels in blood, endothelial cells and normal tissue (*e.g.*, brain). Such delivery has

been accomplished using epidermal growth factor (Yang, W. *et al.*, *Cancer Res* 57:4333-4339 (1997)). Because of the selective expression of uPAR in tumors, the cyclic peptides of the present invention are excellent delivery vehicles for this therapeutic moiety.

Other therapeutic agents which can be coupled to the peptide compounds according to the method of the invention are drugs, prodrugs, enzymes for activating pro-drugs, photo-sensitizing agents, gene therapeutics, antisense vectors, viral vectors, lectins and other toxins.

The therapeutic dosage administered is an amount which is therapeutically effective, as is known to or readily ascertainable by those skilled in the art. The dose is also dependent upon the age, health, and weight of the recipient, kind of concurrent treatment(s), if any, the frequency of treatment, and the nature of the effect desired, such as, for example, anti-inflammatory effects or anti-bacterial effect.

Lectins are proteins, commonly derived from plants, that bind to carbohydrates. Among other activities, some lectins are toxic. Some of the most cytotoxic substances known are protein toxins of bacterial and plant origin (Frankel, A.E. *et al.*, *Ann. Rev. Med.* 37:125-142 (1986)). These molecules binding the cell surface and inhibit cellular protein synthesis. The most commonly used plant toxins are ricin and abrin; the most commonly used bacterial toxins are diphtheria toxin and *Pseudomonas* exotoxin A. In ricin and abrin, the binding and toxic functions are contained in two separate protein subunits, the A and B chains. The ricin B chain binds to the cell surface carbohydrates and promotes the uptake of the A chain into the cell. Once inside the cell, the ricin A chain inhibits protein synthesis by inactivating the 60S subunit of the eukaryotic ribosome Endo, Y. *et al.*, *J. Biol. Chem.* 262: 5908-5912 (1987)). Other plant derived toxins, which are single chain ribosomal inhibitory proteins, include pokeweed antiviral protein, wheat germ protein, gelonin, dianthins, momorcharins, trichosanthin, and many others (Strip, F. *et al.*, *FEBS Lett.* 195:1-8 (1986)). Diphtheria toxin and *Pseudomonas* exotoxin A are also single chain proteins, and their binding and toxicity functions reside in separate domains of the same protein chain with full toxin activity requiring proteolytic cleavage between the two domains. *Pseudomonas* exotoxin A has the same catalytic activity as diphtheria toxin. Ricin has been used therapeutically by binding its toxic α -chain, to targeting molecules such as antibodies to enable site-specific delivery of the toxic effect. Bacterial

toxins have also been used as anti-tumor conjugates. As intended herein, a toxic peptide chain or domain is conjugated to a compound of this invention and delivered in a site-specific manner to a target site where the toxic activity is desired, such as a metastatic focus. Conjugation of toxins to protein such as antibodies or other ligands are known in the art (Olsnes, S. *et al.*, *Immunol. Today* 10:291-295 (1989); Vitetta, E.S. *et al.*, *Ann. Rev. Immunol.* 3:197-212 (1985)).

Cytotoxic drugs that interfere with critical cellular processes including DNA, RNA, and protein synthesis, have been conjugated to antibodies and subsequently used for in vivo therapy. Such drugs, including, but not limited to, daunorubicin, doxorubicin, methotrexate, and Mitomycin C are also coupled to the compounds of this invention and used therapeutically in this form.

In another embodiment of the invention, photosensitizers may be coupled to the compounds of the invention for delivery directly to a tumor.

Therapeutic Methods

The methods of this invention may be used to inhibit tumor growth and invasion in a subject or to suppress angiogenesis induced by tumors by inhibiting endothelial cell growth and migration. By inhibiting the growth or invasion of a tumor or angiogenesis, the methods result in inhibition of tumor metastasis. A vertebrate subject, preferably a mammal, more preferably a human, is administered an amount of the compound effective to inhibit tumor growth, invasion or angiogenesis. The compound or pharmaceutically acceptable salt thereof is preferably administered in the form of a pharmaceutical composition as described above.

Doses of the compounds preferably include pharmaceutical dosage units comprising an effective amount of the peptide. By an effective amount is meant an amount sufficient to achieve a steady state concentration *in vivo* which results in a measurable reduction in any relevant parameter of disease and may include growth of primary or metastatic tumor, any accepted index of inflammatory reactivity, or a measurable prolongation of disease-free interval or of survival. For example, a reduction in tumor growth in 20 % of patients is considered efficacious (Frei III, E., *The Cancer Journal* 3:127-136 (1997)). However, an

effect of this magnitude is not considered to be a minimal requirement for the dose to be effective in accordance with this invention.

In one embodiment, an effective dose is preferably 10-fold and more preferably 100-fold higher than the 50% effective dose (ED₅₀) of the compound in an *in vivo* assay as described herein.

The amount of active compound to be administered depends on the precise peptide or derivative selected, the disease or condition, the route of administration, the health and weight of the recipient, the existence of other concurrent treatment, if any, the frequency of treatment, the nature of the effect desired, for example, inhibition of tumor metastasis, and the judgment of the skilled practitioner.

A preferred dose for treating a subject, preferably mammalian, more preferably human, with a tumor is an amount of up to about 100 milligrams of active compound per kilogram of body weight. A typical single dosage of the peptide or peptidomimetic is between about 1 ng and about 100mg/kg body weight. For topical administration, dosages in the range of about 0.01-20% concentration (by weight) of the compound, preferably 1-5%, are suggested. A total daily dosage in the range of about 0.1 milligrams to about 7 grams is preferred for intravenous administration. The foregoing ranges are, however, suggestive, as the number of variables in an individual treatment regime is large, and considerable excursions from these preferred values are expected.

An effective amount or dose of the peptide for inhibiting invasion *in vitro* is in the range of about 1 picogram to about 0.5 nanograms per cell. Effective doses and optimal dose ranges may be determined *in vitro* using the methods described herein.

The compounds of the invention may be characterized as producing an inhibitory effect on cell migration and invasion, tumor cell and endothelial cell proliferation, on angiogenesis, on tumor metastasis or on inflammatory reactions. The compounds are especially useful in producing an anti-tumor effect in a mammalian host, preferably human, harboring a tumor.

The foregoing compositions and treatment methods are useful for inhibiting cell migration and invasion or cell proliferation in a subject having any disease or condition


associated with undesired cell invasion, proliferation, angiogenesis or metastasis. Such diseases or conditions may include primary growth of solid tumors or leukemias and lymphomas, metastasis, invasion and/or growth of tumor metastases, benign hyperplasias, atherosclerosis, myocardial angiogenesis, post-balloon angioplasty vascular restenosis, neointima formation following vascular trauma, vascular graft restenosis, coronary collateral formation, deep venous thrombosis, ischemic limb angiogenesis, telangiectasia, pyogenic granuloma, corneal diseases, rubeosis, neovascular glaucoma, diabetic and other retinopathy, retrolental fibroplasia, diabetic neovascularization, macular degeneration, endometriosis, arthritis, fibrosis associated with chronic inflammatory conditions including psoriasis scleroderma, lung fibrosis, chemotherapy-induced fibrosis, wound healing with scarring and fibrosis, peptic ulcers, fractures, keloids, and disorders of vasculogenesis, hematopoiesis, ovulation, menstruation, pregnancy and placentation, or any other disease or condition in which invasion or angiogenesis is pathogenic or undesired.

More recently, it has become apparent that angiogenesis inhibitors may play a role in preventing inflammatory angiogenesis and gliosis following traumatic spinal cord injury, thereby promoting the reestablishment of neuronal connectivity (Wamil, A.W. *et al.*, *Proc. Nat'l. Acad. Sci. USA* 95:13188-13193 (1998)). Therefore, the compositions of the present invention are administered as soon as possible after traumatic spinal cord injury and for several days up to about two weeks thereafter to inhibit the angiogenesis and gliosis that would sterically prevent reestablishment of neuronal connectivity. The treatment reduces the area of damage at the site of spinal cord injury and facilitates regeneration of neuronal function and thereby prevents paralysis. The compounds of the invention are expected also to protect axons from Wallerian degeneration, reverse aminobutyrate-mediated depolarization (occurring in traumatized neurons), and improve recovery of neuronal conductivity of isolated central nervous system cells and tissue in culture.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

EXAMPLE I

Synthesis of



The starting material is MBHA resin substituted at a level of 0.45 mEq/gm resin. Each of the remaining L-amino acids is added in sequence in a synthesis cycle consisting of:

(1) TFA De-protection

The BOC protecting group is removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture is stirred at room temperature for 30 minutes and then drained. The resin is then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

(2) Coupling

The deprotected resin is washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol, each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) is added to the resin and the mixture is stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) is then added and the whole mixture is stirred for 60–120 minutes. The resin is washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample is taken for a ninhydrin test to assess the completeness of

coupling. Generally, if incomplete, the coupling step **2** is repeated. If complete, the synthesis is continued with the capping step **3**.

All amino acids are used as α -BOC derivatives. Side chain protecting groups are as follows:

	Glutamic acid	Cyclohexyl ester
5	Tryptophan	N-Formyl
	Histidine	Benzyloxymethyl
	Asparagine	Xanthyl
	Serine	O-Benzyl
	Tyrosine	2-Bromo-Z
10	Lysine	Trifluoroacetyl
	Cysteine	Acetamidomethyl

(3) Capping

The resin is stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin is washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) is placed in a Teflon reaction vessel, and anhydrous anisole (1mL) is added. The vessel is cooled with liquid N₂, and anhydrous HF (10 mL) is distilled into it. The temperature is raised with iced water to 0°C. The mixture is stirred at this temperature for 1 hour, and then the HF is distilled off at 0°C. The residue is washed with anhydrous ether, and the peptide is extracted with a 1:1 mixture of CH₃CN:H₂O.

(5) Cyclization

The linear peptide (0.1 mmole) is dissolved in DMSO (50 mL), and the resulting solution is diluted with DMF (100 mL). TBTU (5 equivalents) and HOBt (5 equivalents) are added to the solution; these reagents dissolve. The pH is adjusted to 7.5-8.0 with N,N-diisopropylethylamine. Cyclization is monitored by analytical HPLC and is found to be complete after 120 minutes.

(6) Purification

The above cyclic peptide solution is acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.

(7) Removal of the Trifluoroacetyl Protecting Group

The pure, (ϵ -TFA)-Lys-protected peptide is dissolved in a mixture of dioxane-water (1:1) and the resulting solution is diluted 2-fold with 0.2N NaOH_{aq}. After 15 minutes the mixture is acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

(8) Removal of the Acetamidomethyl Protecting Group


The pure, acetamidomethyl-protected peptide is dissolved in 1M acetic acid (approximately 10 mL of acetic acid per millimole of peptide). Mercuric chloride (1.1) equivalents dissolved in 1M aqueous acetic acid (5 mL per millimole of peptide) is added to the peptide solution. The mixture is stirred at room temperature for 2 hours. The resulting mercury complex is decomposed by the addition of a large excess (10 equivalents) of 2-mercapto-ethanol. The precipitate is filtered off and is washed with 1M aqueous acetic acid (2 mL). The filtrate is directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B

and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

5

EXAMPLE II

Synthesis of:



The starting material is MBHA resin substituted at a level of 0.45 mEq/gm resin. Each of the remaining L-amino acids is added in sequence in a synthesis cycle consisting of:

10

(1) TFA De-protection

The BOC protecting group is removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture is stirred at room temperature for 30 minutes and then drained. The resin is then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

15

(2) Coupling

The deprotected resin is washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol, each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) is added to the resin and the mixture is stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three

20

equivalents) is then added and the whole mixture is stirred for 60–120 minutes. The resin is washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample is taken for a ninhydrin test to assess the completeness of coupling. Generally, if incomplete, the coupling step **2** is repeated. If complete, the synthesis is continued with the capping step **3**.

All amino acids are used as α -BOC derivatives. Side chain protecting groups are as follows:

Glutamic acid	Cyclohexyl ester
Tryptophan	N-Formyl
Histidine	Benzyloxymethyl
Asparagine	Xanthyl
Serine	O-Benzyl
Tyrosine	2-Bromo-Z
Lysine	Trifluoroacetyl
Homocysteine	Acetamidomethyl

(3) Capping

The resin is stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin is washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) is placed in a Teflon reaction vessel, and anhydrous anisole (1mL) is added. The vessel is cooled with liquid N_2 , and anhydrous HF (10 mL) is distilled into it. The temperature is raised with iced water to 0°C . The mixture is stirred at this temperature for 1 hour, and then the HF is distilled off at 0°C . The residue is washed with anhydrous ether, and the peptide is extracted with a 1:1 mixture of $\text{CH}_3\text{CN}:\text{H}_2\text{O}$.

(5) Cyclization

The linear peptide (0.1 mmole) is dissolved in DMSO (50 mL), and the resulting solution is diluted with DMF (100 mL). TBTU (5 equivalents) and HOBt (5 equivalents) are added to the solution; these reagents dissolve. The pH is adjusted to 7.5–8.0 with N,N-

diisopropylethylamine. Cyclization is monitored by analytical HPLC and is found to be complete after 120 minutes.

(6) Purification

The above cyclic peptide solution is acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.

(7) Removal of the Trifluoroacetyl Protecting Group

The pure, (ϵ -TFA)-Lys-protected peptide is dissolved in a mixture of dioxane-water (1:1) and the resulting solution is diluted 2-fold with 0.2N NaOH_{aq}. After 15 minutes the mixture is acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.


(8) Removal of the Acetamidomethyl Protecting Group

The pure, acetamidomethyl-protected peptide is dissolved in 1M acetic acid (approximately 10 mL of acetic acid per millimole of peptide). Mercuric chloride (1.1) equivalents dissolved in 1M aqueous acetic acid (5 mL per millimole of peptide) is added to the peptide solution. The mixture is stirred at room temperature for 2 hours. The resulting mercury complex is decomposed by the addition of a large excess (10 equivalents) of 2-mercapto-ethanol. The precipitate is filtered off and is washed with 1M aqueous acetic acid

(2 mL). The filtrate is directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μm particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H_2O and solution B is 0.1% TFA in CH_3CN . Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

EXAMPLE III

Synthesis of:



The starting material is MBHA resin substituted at a level of 0.45 mEq/gm resin. Each of the remaining L-amino acids is added in sequence in a synthesis cycle consisting of:

(1) TFA De-protection

The BOC protecting group is removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture is stirred at room temperature for 30 minutes and then drained. The resin is then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

(2) Coupling

The deprotected resin is washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol,

each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) is added to the resin and the mixture is stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) is then added and the whole mixture is stirred for 60–120 minutes. The resin is washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample is taken for a ninhydrin test to assess the completeness of coupling. Generally, if incomplete, the coupling step 2 is repeated. If complete, the synthesis is continued with the capping step 3.

All amino acids are used as α -BOC derivatives. Side chain protecting groups are as follows:

Glutamic acid	Cyclohexyl ester
Tryptophan	N-Formyl
Histidine	Benzyloxymethyl
Asparagine	Xanthyl
Serine	O-Benzyl
Tyrosine	2-Bromo-Z
Lysine	Fluorenylmethyloxycarbonyl
Aspartic Acid	Fluorenylmethyl

(3) Capping

The resin is stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin is washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) is placed in a Teflon reaction vessel, and anhydrous anisole (1 mL) is added. The vessel is cooled with liquid N₂, and anhydrous HF (10 mL) is distilled into it. The temperature is raised with iced water to 0°C. The mixture is stirred at this temperature for 1 hour, and then the HF is distilled off at 0°C. The residue is washed with anhydrous ether, and the peptide is extracted with a 1:1 mixture of CH₃CN:H₂O.

(5) Cyclization

The linear peptide (0.1 mmole) is dissolved in DMSO (50 mL), and the resulting solution is diluted with DMF (100 mL). TBTU (5 equivalents) and HOBt (5 equivalents) are added to the solution; these reagents dissolve. The pH is adjusted to 7.5-8.0 with N,N-diisopropylethylamine. Cyclization is monitored by analytical HPLC and is found to be complete after 120 minutes.

(6) Purification


The above cyclic peptide solution is acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.

(7) Removal of the Fluorenylmethyl-containing Protecting Groups

The pure, (ε-Fluorenylmethyloxycarbonyl)-Lys-(β-Fluorenylmethyl)-Asp-protected peptide is dissolved in a mixture of dioxane-water (1:1) and the resulting solution is diluted 2-fold with 0.2N NaOH_{aq}. After 15 minutes the mixture is acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

EXAMPLE IV

Synthesis of:



The starting material is MBHA resin substituted at a level of 0.45 mEq/gm resin.

Each of the remaining L-amino acids is added in sequence in a synthesis cycle consisting of:

(1) TFA De-protection

The BOC protecting group is removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture is stirred at room temperature for 30 minutes and then drained. The resin is then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

(2) Coupling

The deprotected resin is washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol, each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBt) (1M solution in DMF, three equivalents) is added to the resin and the mixture is stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) is then added and the whole mixture is stirred for 60–120 minutes. The resin is washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample is taken for a ninhydrin test to assess the completeness of

coupling. Generally, if incomplete, the coupling step 2 is repeated. If complete, the synthesis is continued with the capping step 3.

All amino acids are used as α -BOC derivatives. Side chain protecting groups are as follows:

5	Glutamic acid exocyclic	Fluorenylmethyl
	Glutamic acid endocyclic	Cyclohexyl ester
	Tryptophan	N-Formyl
	Histidine	Benzyloxymethyl
	Asparagine	Xanthyl
10	Serine	O-Benzyl
	Tyrosine	2-Bromo-Z
	Lysine	Fluorenylmethyloxycarbonyl

(3) Capping

The resin is stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin is washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) is placed in a Teflon reaction vessel, and anhydrous anisole (1mL) is added. The vessel is cooled with liquid N₂, and anhydrous HF (10 mL) is distilled into it. The temperature is raised with iced water to 0°C. The mixture is stirred at this temperature for 1 hour, and then the HF is distilled off at 0°C. The residue is washed with anhydrous ether, and the peptide is extracted with a 1:1 mixture of CH₃CN:H₂O.

(5) Cyclization


The linear peptide (0.1 mmole) is dissolved in DMSO (50 mL), and the resulting solution is diluted with DMF (100 mL). TBTU (5 equivalents) and HOBT (5 equivalents) are added to the solution; these reagents dissolve. The pH is adjusted to 7.5-8.0 with N,N-diisopropylethylamine. Cyclization is monitored by analytical HPLC and is found to be complete after 120 minutes.

(6) Purification


The above cyclic peptide solution is acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μm particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H_2O and solution B is 0.1% TFA in CH_3CN . Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.

(7) Removal of the Fluorenylmethyl-containing Protecting Groups

The pure, (ϵ -Fluorenylmethoxycarbonyl)-Lys-(γ -Fluorenylmethyl)-Glu-protected peptide is dissolved in a mixture of dioxane-water (1:1) and the resulting solution is diluted 2-fold with 0.2N NaOH_{aq} . After 15 minutes the mixture is acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μm particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H_2O and solution B is 0.1% TFA in CH_3CN . Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

EXAMPLE VSynthesis of:

4-((9-Fluorenylmethoxycarbonyl)amino)aniline is prepared from *p*-phenylenediamine (2.16 g, 0.02 mole) and N-(9-fluorenylmethoxycarbonyloxy)succinimide (6.75 g, 0.02 mole) in dioxane-water (1:1). Purification is achieved by crystallization. This product is coupled to BOC-L-Glu- α -O-Benzyl using HOBT/DCC. After the usual work-up, the fully-protected amino acid derivative is dissolved in MeOH and treated with hydrogen gas at 1 atmosphere pressure in the presence of palladium-on-carbon catalyst until hydrogen consumption is complete (about 2 hours). Following the usual workup, the starting material:



is obtained. It is coupled to the MBHA resin at a level of 0.45 mEq/gm resin. Each of the remaining L-amino acids is added in sequence in a synthesis cycle consisting of:

(1) TFA De-protection

The BOC protecting group is removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM)

(two to three volumes per resin volume). The mixture is stirred at room temperature for 30 minutes and then drained. The resin is then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

5 (2) Coupling

The deprotected resin is washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol, each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) is added to the resin and the mixture is stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) is then added and the whole mixture is stirred for 60–120 minutes. The resin is washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample is taken for a ninhydrin test to assess the completeness of coupling. Generally, if incomplete, the coupling step 2 is repeated. If complete, the synthesis is continued with the capping step 3.

All amino acids are used as a-BOC derivatives. Side chain protecting groups are as follows:

Glutamic acid	Cyclohexyl ester
Tryptophan	N-Formyl
Histidine	Benzyloxymethyl
Asparagine	Xanthyl
Serine	O-Benzyl
Tyrosine	2-Bromo-Z
Lysine	Trifluoroacetyl

(3) Capping

The resin is stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin is washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) is placed in a Teflon reaction vessel, and anhydrous anisole (1mL) is added. The vessel is cooled with liquid N₂, and anhydrous HF (10 mL) is distilled into it. The temperature is raised with iced water to 0°C. The mixture is stirred at this temperature for 1 hour, and then the HF is distilled off at 0°C. The residue is washed with anhydrous ether, and the peptide is extracted with a 1:1 mixture of CH₃CN:H₂O.

(5) Cyclization

The linear peptide (0.1 mmole) is dissolved in DMSO (50 mL), and the resulting solution is diluted with DMF (100 mL). TBTU (5 equivalents) and HOBT (5 equivalents) are added to the solution; these reagents dissolve. The pH is adjusted to 7.5-8.0 with N,N-diisopropylethylamine. Cyclization is monitored by analytical HPLC and is found to be complete after 120 minutes.

(6) Purification

The above cyclic peptide solution is acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 µm particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.


(7) Removal of the Trifluoroacetyl Protecting Group

The pure, (ε-TFA)-Lys-protected peptide is dissolved in a mixture of dioxane-water (1:1) and the resulting solution is diluted 2-fold with 0.2N NaOH_{aq}. After 15 minutes the mixture is acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 µm particle size, 300Å pore size). The loaded column is eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B.


Solution A is 0.1% TFA in H₂O and solution B is 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired are pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

EXAMPLE VI

Synthesis of:



The starting material (designated Å4) having the formula




was synthesized as described below in Example XI. Two mg were dissolved in 100 mM MES pH 5.0 (0.5 mL) to a final concentration of 2.5 mM (4 mg/mL). Stock solutions of *p*-phenylenediamine (PPD; 10 mg/mL) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; 10 mg/mL) were also prepared in 100 mM MES pH 5.0. EDC (50 µL of 10 mg/mL stock) and PPD (100 µL of 10 mg/mL stock) were added to 0.5 mL of the starting material solution, resulting in a molar ratio of approximately 2: 2: 1 (EDC: PPD: starting material). The mixture was allowed to incubate for 3 hours at room temperature, followed by HPLC purification on a C₈ reverse-phase column (linear gradient over 30 minutes; mobile phase A: 100% H₂O/0.1 % TFA; mobile phase B: 100% acetonitrile/0.1% TFA). Under these conditions, the reaction goes to greater than 90% completion, yielding the desired product (RTLPPD) as the major component.

The synthesis of the isomer (RTLMPD) incorporating *m*-phenylenediamine (MPD) and the isomer (RTLOPD) incorporating *o*-phenylenediamine (OPD) followed this same scheme and gave similar yields.

EXAMPLE VII


Synthesis of:



RTLPPD was synthesized as in Example VI. One mg was dissolved in 100 mM Phosphate Buffer pH 6.8 (1.5 mL) to a final concentration of 0.38 mM. Oregon Green (Difluorofluorescein isothiocyanate; 10 mg) was dissolved in DMSO (1 mL). Oregon Green (20 μ L) was added to the RTLPPD solution (0.5 mL) in a polypropylene Eppendorf tube. The tube was wrapped in foil and the mixture was incubated on a rocker table for 6 hours at 22°C. The Oregon Green-labeled product was purified by HPLC using the same conditions as described in Example VI. Since the Oregon Green isothiocyanate precursor is a mixture of two positional isomers at 5 and 6, so too is the product.


EXAMPLE VIII

Synthesis of:




RTLPPD (1 mg) was dissolved in 100 mM Phosphate Buffer pH 6.8 (1.5 mL) to a final concentration of 0.38 mM. Biotin-X-*sulfo*NHS (where X is a 7-atom spacer; 10 mg) was dissolved in this same buffer (1 mL). Biotin-X-*sulfo*NHS (20 μ L) was then added to the RTLPPD solution (0.5 mL) in a polypropylene Eppendorf tube and the mixture was incubated on a rocker table for 3 hours at 22°C. Excess, non-reacted Biotin-X-NHS was removed from the mixture by dialysis using a 2000 molecular weight cutoff membrane. The product was further purified by HPLC as described in Example VI.


Synthesis of:



5

EXAMPLE XSynthesis of:

RTLPPD (1 mg) was dissolved in 100 mM Phosphate Buffer pH 6.8 (1.5 mL) to a final concentration of 0.38 mM. DTPA anhydride (Diethylenetriaminepentaacetic acid anhydride, 1mg) was then added to the RTLPPD solution (0.5 mL) in a polypropylene Eppendorf tube and the mixture was incubated on a rocker table for 3 hours at 22°C. The product was purified by HPLC as described in Example VI.

EXAMPLE XISynthesis of A4:

The starting material was BOC-Gly-O-resin substituted at a level of 0.80 mEq/gm resin. Each of the remaining L-amino acids was added in sequence in a synthesis cycle consisting of the following steps.

(1) TFA De-protection

The BOC protecting group was removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture was stirred at room temperature for 30 minutes and then drained. The resin was washed once with an equal volume of isopropanol for one minute and twice with an equal volume of methanol, each wash taking one minute.

(2) Coupling

The deprotected resin was washed twice with an equal volume of 10% triethylamine in DCM, twice with an equal volume of methanol, and twice with an equal volume of DCM, each wash for one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) was added to the resin and the mixture was stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) was then added, and the whole mixture was stirred for 60–120 minutes. The resin was washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM. A small sample was taken for a ninhydrin test to assess the completeness of coupling. Generally, if incomplete, coupling step 2 was repeated. If complete, the synthesis was continued with the capping step 3.

In the case of BOC-L-Glu(Fm)-OH, coupling was only partly complete and therefore was repeated.

All amino acids were used as α -BOC derivatives. Side chain protecting groups were as follows:

Glutamic acid	Fluorenylmethyl ester
Tryptophan	N-Formyl
Histidine	Benzyloxymethyl
Asparagine	Xanthyl
Serine	O-Benzyl

Tyrosine	2-Bromo-Z
Lysine	2-Chloro-Z

The final N-terminal glycine was coupled as Fmoc-Gly-OH

(3) Capping

The resin was stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin was washed twice with an equal volume of methanol and then washed twice with an equal volume of DCM.

(4) Cyclization

After the final capping cycle, the N-terminal Fmoc, the α -fluorenylmethyl, and the N-formyl protecting groups were removed by treatment with 20% piperidine in DMF at room temperature for 30 minutes. Cyclization was accomplished by adding 3 equivalents of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 3 equivalents of HOBT to the resin. The pH was adjusted to 7.5-8.0 with N,N-diisopropyl-ethylamine. Cyclization was monitored by the ninhydrin test and was found to be complete after 60 minutes.

(5) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) was placed in a Teflon reaction vessel and anhydrous anisole (1 mL) was added. The vessel was cooled with liquid N₂ and anhydrous HF (10 mL) was distilled into it. The temperature was raised with iced water to 0°C. The mixture was stirred at this temperature for 1 hour and then the HF was distilled off at 0°C. The residue was washed with anhydrous ether, and the peptide was extracted with a 1:1 mixture of CH₃CN:H₂O.


(6) Purification

The crude lyophilized peptide was dissolved in a solution of 0.1% TFA in H₂O and loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column was eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A was 0.1% TFA in H₂O and solution B was 0.1% TFA in

CH₃CN. Fractions exhibiting purity equal to or better than that desired were pooled and lyophilized to render the purified final product as the trifluoroacetate salt.

EXAMPLE XII

Synthesis of Å5:



The starting material was MBHA resin substituted at a level of 0.45 mEq/gm resin. Each of the remaining L-amino acids was added in sequence in a synthesis cycle consisting of:

(1) TFA De-protection

The BOC protecting group was removed from the α -amino nitrogen of the starting material by treating the resin with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) (two to three volumes per resin volume). The mixture was stirred at room temperature for 30 minutes and then drained. The resin was then washed once with an equal volume of isopropanol for one minute and then washed twice with an equal volume of methanol, each wash taking one minute.

(2) Coupling

The deprotected resin was washed twice with an equal volume of 10% triethylamine in DCM, each wash taking one minute, and washed twice with an equal volume of methanol, each wash taking one minute, and washed twice with an equal volume of DCM, each wash taking one minute. A BOC-protected amino acid (three equivalents, dissolved in DCM or in a mixture of DCM and N,N-dimethylformamide (DMF)) and 1-hydroxybenzotriazole (HOBT) (1M solution in DMF, three equivalents) was added to the resin and the mixture was stirred for a few seconds. Dicyclohexylcarbodiimide (DCC) (1M solution in DCM, three equivalents) was then added and the whole mixture was stirred for 60–120 minutes. The resin was washed twice with an equal volume of methanol and then washed twice with an

equal volume of DCM. A small sample was taken for a ninhydrin test to assess the completeness of coupling. Generally, if incomplete, the coupling step 2 was repeated. If complete, the synthesis was continued with the capping step 3.

All amino acids were used as α -BOC derivatives. Side chain protecting groups were as follows:

Glutamic acid	Cyclohexyl ester
Tryptophan	N-Formyl
Histidine	Benzyloxymethyl
Asparagine	Xanthyl
Serine	O-Benzyl
Tyrosine	2-Bromo-Z
Lysine	Trifluoroacetyl

(3) Capping

The resin was stirred with an equal volume of acetic anhydride (20% solution in DCM) for 5 minutes at room temperature. The resin was washed twice with an equal volume of methanol and twice with an equal volume of DCM.

(4) HF Cleavage

The resin bearing the desired amino acid sequence (1.0 gram) was placed in a Teflon reaction vessel, and anhydrous anisole (1mL) was added. The vessel was cooled with liquid N_2 , and anhydrous HF (10 mL) was distilled into it. The temperature was raised with iced water to $0^\circ C$. The mixture was stirred at this temperature for 1 hour, and then the HF was distilled off at $0^\circ C$. The residue was washed with anhydrous ether, and the peptide was extracted with a 1:1 mixture of $CH_3CN:H_2O$.

(5) Cyclization

The linear peptide (0.1 mmole) was dissolved in DMSO (50 mL), and the resulting solution was diluted with DMF (100 mL). TBTU (5 equivalents) and HOBT (5 equivalents) were added to the solution; these reagents dissolved. The pH was adjusted to 7.5-8.0 with N,N -diisopropylethylamine. Cyclization was monitored by analytical HPLC and was found to be complete after 120 minutes.

(6) Purification


The above cyclic peptide solution was acidified to pH 4.0, diluted 5-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column was eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A was 0.1% TFA in H₂O and solution B was 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired were pooled and lyophilized to render the purified, trifluoroacetyl-protected product as the trifluoroacetate salt.

(7) Removal of the Trifluoroacetyl Protecting Group


The pure, (α -TFA)-Lys-protected peptide was dissolved in a mixture of dioxan-water (1:1) and the resulting solution was diluted 2-fold with 0.2N NaOH_{aq}. After 15 minutes the mixture was acidified to pH 4.0, diluted 3-fold with water, and directly loaded onto a Waters C18 preparative column (2 inches diameter, 15-20 μ m particle size, 300Å pore size). The loaded column was eluted with a two-component eluent applied as a linear gradient, starting with 15% of solution A in solution B and finishing with 40% of solution A in solution B. Solution A was 0.1% TFA in H₂O and solution B was 0.1% TFA in CH₃CN. Fractions exhibiting purity equal to or better than that desired were pooled and lyophilized to render the purified, final product as the trifluoroacetate salt.

EXAMPLE XIII

Synthesis of Å36:



Cyclic peptide Å36 was synthesized from Å4 (see Example XI) as starting material



This cyclic peptide can be characterized as comprising a linker L having the formula
 $\text{-CO-CH}_2\text{-NH-CO-CH}_2\text{-CH}_2\text{CH(CO-NH-CH}_2\text{-CO-NH-Phe)-NH-}$

MES buffer was prepared by dissolving 2-(N-morpholino)ethanesulfonic acid in
 5 water at a concentration of 0.1M and adjusting the pH to 5.0 using aqueous 5N NaOH. To a
 stirred solution of the starting cyclic peptide (0.405 g, 0.25 mmol) in a mixture of MES
 buffer (80 mL) and CH_3CN (20 mL) was added a solution of aniline (0.400 g, 4.3 mmol, 17.2
 equiv) in dimethyl sulfoxide (10 mL) followed by a solution of 1-ethyl-3-(3-
 dimethylaminopropyl)carbodiimide hydrochloride (0.192 g, 1 mmol, 4.0 equiv) in MES
 10 buffer (20 mL).

The resulting solution was kept at room temperature for 12 hours. It was then loaded
 onto a Vydac C-18 preparative reverse-phase silica HPLC column (15-20 μM particle size,
 diameter 2 inches, length 12 inches) and the column was washed with 2 column volumes of
 TEAP buffer, pH 2.25 (prepared by dissolving triethylamine (10 mL) and 85% H_3PO_4 (10
 15 mL) in water and bringing the volume to 1000 mL) The column was then eluted with a two-
 component eluent applied as a linear gradient during 40 min, starting with 20% of CH_3CN in
 TEAP buffer and finishing with 50% of CH_3CN in TEAP buffer. The flow rate was 100
 mL/min.

The fractions eluting between 20 and 25 min were collected, and each was analyzed
 20 by analytical HPLC using a Vydac C-18 reverse-phase silica column (5 μM particle size,
 diameter 4.6 mm, length 254 mm) eluted with a two-component eluent applied as a linear
 gradient during 20 min, starting with 20% of solution A in solution B and finishing with 50%
 of solution A in solution B. Solution A was 0.1% trifluoroacetic acid (TFA) in H_2O and
 solution B was 0.1% TFA in CH_3CN . The flow rate was 1.5 mL/min. Those fractions
 25 showing better than 95% purity were pooled and reloaded onto the preparative HPLC

column and desalted by washing the column with 2.5 column volumes of 0.1% aqueous TFA solution.

When desalting was complete, the column was eluted with a two-component eluent applied as a linear gradient during 50 min, starting with 20% of solution A in solution B and finishing with 50% of solution A in solution B. Solution A was 0.1% TFA in H₂O and solution B was 0.1% TFA in CH₃CN. Fractions containing pure material according to analytical HPLC as above were pooled and lyophilized to render the final product trifluoroacetate salt as a white powder of 98.8% purity.

EXAMPLE XIV (XI)

Binding of Cyclic Peptides to RKO Cells

The compounds of the invention were tested for their binding to uPAR by measuring their ability to inhibit the binding of [¹²⁵I]DFP-uPA (catalytically inactivated high molecular weight uPA) to uPAR expressed by RKO (human colon carcinoma) cells. Cells (about 5 x 10⁴/well) were plated (in MEM with Earle's salts/10% FBS + antibiotics) in 24-well plates, then incubated in a humid 5% CO₂ atmosphere until the cells reach 70% confluence. Catalytically inactivated high molecular weight uPA (DFP-uPA) was radioiodinated using Iodo-gen[®] (Pierce) to a specific activity of about 250,000 cpm/mg. The cell-containing plates were then chilled on ice and the cells were washed twice (5 minutes each) with cold PBS/ 0.05% Tween-80. Test compounds were serially diluted in cold PBS/ 0.1 % BSA/ 0.01% Tween-80 and added to each well to a final volume of 0.3mL 10 minutes prior to the addition of the [¹²⁵I]DFP-uPA. Each well then receives 9500 cpm of [¹²⁵I]DFP-uPA at a final concentration of 0.2 nM. The plates were incubated at 4°C for 2 hrs, after which time the cells were washed 3x (5 minutes each) with cold PBS/ 0.05% Tween-80. NaOH (1N; 0.5 mL) was added to each well to lyse the cells, the contents of each well were aspirated and the total counts in each well determined using a gamma counter. Each compound was tested in triplicate and the results are expressed as a percentage of the total radioactivity measured in wells containing [¹²⁵I]DFP-uPA alone, which is taken to represent maximum (100 %) binding.

RTLPPD inhibited the binding of [125 I]DFP-uPA with an IC_{50} of approximately 5 nM (Figure 3). Modification of RTLPPD with Oregon Green shifted the IC_{50} to approximately 800 nM (Figure 3) and modification with biotin shifted the IC_{50} to approximately 1.1 μ M (Figure 4). RTLMPD and RTLOPD inhibited the binding of [125 I]DFP-uPA to RKO cells with an IC_{50} of approximately 50 and 100 nM, respectively (Figure 3).

EXAMPLE XV (XII)

Inhibition of PC-3 Tumor Cell Invasion

The ability of PC-3 (human prostatic carcinoma) cells to invade through a reconstituted basement membrane (Matrigel®) was measured using transwell tissue culture inserts. Transwells (Costar) containing polycarbonate membranes (8.0 μ m pore size) were coated with Matrigel® (Collaborative Research), which had been diluted in sterile PBS to a final concentration of 75 μ g/mL (60 μ L of diluted Matrigel® per insert), and placed in the wells of a 24-well plate. The membranes were dried overnight in a biological safety cabinet, then rehydrated by adding 100 μ L of DMEM containing antibiotics for 1 hour on a shaker table. The DMEM was removed from each insert by aspiration and 0.8 mL of DMEM/10 % FBS/antibiotics was added to the lower chamber of each well of a 24-well plate. Fresh DMEM/ antibiotics (100 μ L), human Glu-plasminogen (5 μ g/mL), and RTLPPD (1 μ M and 200 nM) were added to the upper chamber. Tumor cells were trypsinized and resuspended in DMEM/antibiotics, then added to the top chamber of the transwell at a final concentration of 800,000 cells/mL. The final volume of the upper chamber was adjusted to 200 μ L and the assembled plate was incubated in a humid 5% CO₂ atmosphere for 72 hours. After incubation, the cells were fixed and stained using DiffQuik® (Giemsa stain). The upper chamber was then scraped using a cotton swab to remove the Matrigel® and any cells which did not invade through the membrane. The membranes were detached from the transwell using an X-acto® blade, mounted on slides using Permount® and cover-slips, then counted under a high-powered (400x) field. An average of the cells invaded was determined from 5 fields counted and plotted as a function of inhibitor concentration. RTLPPD inhibited the invasion of PC-3 cells by greater than 50% at both concentrations tested (Figure 5).

EXAMPLE XVI (XIII)**Oregon Green-labeled-RTLPPD Targeting to Stimulated Endothelial Cells**

The ability of Oregon Green-labeled-RTLPPD to localize to stimulated endothelial cells was
 assessed by fluorescence microscopy. HUVECs were cultured for 24 hours on coverslips (in
 a 6-well plate) in the presence (10 ng/mL FGF-2 and 10 ng/mL VEGF) and absence of
 angiogenic stimulators, as might typically be found in a tumor. Oregon Green-labeled-
 RTLPPD (1 μ M) was added to each well and allowed to incubate in the presence of the cells.
 The coverslips were removed from the wells and washed twice (5 minutes per wash) with
 PBS in a second 6-well plate. The coverslips were mounted onto slides and the fluorescence
 observed using a fluorescent microscope. Digitized images were captured using a video
 camera and NIH image. Binding of Oregon Green-labeled-RTLPPD was only observed to
 the stimulated cells. Furthermore, the binding pattern observed with Oregon Green-labeled-
 RTLPPD localized to the pseudopodia and focal adhesions of the cells, consistent with the
 previously described distribution of uPAR on migrating or adherent cell surfaces (Figure 6).

EXAMPLE XVII (XIV)**Inhibition of Angiogenesis *In Vivo* by uPAR-targeting Ligands**

Angiogenesis induced by tumor growth and metastasis *in vivo* is examined in the
 models systems described above. Mice injected with 3LL cells are treated either with the
 cyclic peptide derivative or with vehicle and are sacrificed at various time points.
 Angiogenesis is assessed by determining microvessel density (MVD) using an antibody
 specific for microvascular endothelium or other markers of growing blood vessels, such as
 PECAM (CD31). Such an antibody is employed in conventional immunohistological
 methods to immunostain tissue sections as described by Penfold *et al.*, *Br. J. Oral and*
Maxill. Surg. 34: 37-41. A large number of such antibodies is commercially available, for
 example the JC70 mAb. The MVD is correlated with other measures of tumor behavior
 including lymph node status and primary tumor size and rate of growth. In humans as
 reported by Penfold *et al.*, *supra*, tumor MVD correlates with lymph node metastasis and is

independent of tumor size, growth rate or type of histological differentiation. Only MVD showed a significant association with lymph node metastasis.

The compounds are given i.p. Typical dosages are 4-10 mg/kg/day. At various time points, two animals are sacrificed, and the tumor tissue and surrounding tissue is prepared for histological examination. Results are reported as the average microvessel density of 5 fields each from 5 different sections.

The cyclic peptide derivative of Example VI, comprising the natural uPA sequence at positions X¹ through X¹¹ corresponding to the mouse sequence [SEQ ID NO:4] was cyclized using the L10 linker (R²=*p*-phenylene). This compound is termed "murine RTLPPD." In mice treated with murine RTLPPD, there is a significant reduction in the number of microvessels in the region of the primary tumor at the subcutaneous inoculation site as compared to controls. Control cyclic peptides in this and subsequent examples have the Tyr, Phe and (in the case of human, Trp) positions replaced with Ala residues. Such peptides have no detectable binding to uPAR. Here, cyclic peptide derivatives having the Ala substitutions have no significant effect on angiogenesis. Therefore, murine RTLPPD has anti-angiogenic activity which is responsible at least in part for its effectiveness as an antitumor agent.

Additional compounds having the L10 linker and either *o*- or *m*-phenylenediamine are tested in this model, as are cyclic peptides comprising the other L groups disclosed above, and having *p*-, *o*- or *m*-phenylene as the R² group and have similar biological effects *in vivo*. Similar effects are observed using the substituted amino acid sequences described above. Murine RTLPPD and its derivatives to which ¹³¹I is conjugated (either 1 or 2 I atoms per molecule of cyclic peptide) are effective radiotherapeutics and are found to be at least two-fold more potent than their unconjugated analogues.


EXAMPLE XVIII (XV)

Inhibition of Spontaneous Metastasis *In Vivo* by uPAR-targeting Ligand Derivatives

The rat syngeneic breast cancer system (Xing *et al.*, *Int. J. Cancer* 67:423-429 (1996)) employs Mat BIII rat breast cancer cells. Tumor cells, 1 x 10⁶ suspended in 0.1 mL PBS are

inoculated into the mammary fat pads of 10 female Fisher rats. At the time of inoculation, a 14-day Alza osmotic mini-pump is implanted intraperitoneally to dispense the peptide. The peptide is dissolved in PBS (200 mM stock), sterile filtered and placed in the minipump to achieve a dispensing rate of about 4 mg/kg/day. Control animals receive vehicle (PBS) alone or an Ala-substituted control peptide in the minipump. Animals are euthanized at day 14.

In this study uPAR-targeting ligands are made based on the rat amino acid sequences of the uPAR-binding domain of uPA. Thus in parallel to human sequence RTLPPD, the following compound, "rat RTLPPD" is tested:



In the rats treated with this and related cyclic peptide derivatives, there is a significant reduction in the size of the primary tumor and in the number of metastases in the spleen, lungs, liver, kidney and lymph nodes (enumerated as discrete foci). Upon histological and immunohistochemical analysis, it is seen that in treated animals, there is increased necrosis and signs of apoptosis. Large necrotic areas are seen in tumor regions lacking in neovascularization. Rat RTLPPD and its derivatives to which ^{131}I is conjugated (either 1 or 2 I atoms per molecule of cyclic peptide) are effective radiotherapeutics and are found to be at least two-fold more potent than their unconjugated analogues.

In contrast, treatment with control cyclic peptides failed to cause a significant change in tumor size or metastasis.

EXAMPLE XIX (XVI)Inhibition of Growth of Human Tumors *In Vivo* by uPAR-targeting Ligand Derivatives

The ability of the uPAR-targeting cyclic peptides are tested for their ability to inhibit the local growth of a human tumor in a nude mouse model, as described above. Nude mice are inoculated s.c. in their right flanks with 1×10^6 cells MDA-MB-231 human breast carcinoma cells and Matrigel® in a volume of 0.2mL). The tumors are staged to 200 mm³ and then treatment with the test compounds of the invention is started (100 µg/ animal/day given q.d. I.P). Tumor volumes are measured every other day and the animals are sacrificed after 3 weeks of treatment. The tumors are excised, weighed and paraffin embedded.

Histological sections of the tumors are analyzed histochemically. In mice treated with RTLPPD, there is a significant lower tumor volume compared to vehicle controls and subjects treated with a control cyclic peptide. Therefore, RTLPPD has direct antitumor effects. Histological analysis shows that this agent induced apoptosis in the tumor cells.

Compounds having the L10 linker and either *o*- or *m*-phenylenediamine are tested in this model, as are cyclic peptides comprising the other L groups disclosed above, and having *p*-, *o*- or *m*-phenylene as the R² group. All these compounds have similar anti-tumor effects *in vivo*. Similar effects are observed using the substituted amino acid sequences described above. RTLPPD and its derivatives to which ¹³¹I is conjugated (either 1 or 2 I atoms per molecule of cyclic peptide) are effective radiotherapeutics and are found to be at least two-fold more potent than their unconjugated analogues.

EXAMPLE XX (XVII)Inhibition of Experimental Metastasis of Tumor Cells *In Vivo* by uPAR-Targeting Ligand Derivatives

The cyclic peptide derivatives described above are also tested for efficacy *in vivo* in a model of human tumor metastasis in nude mice. PC-3 cells transfected with the gene encoding the enzyme chloramphenicol acetyl-transferase (CAT) are inoculated into nude mice i.v. at doses of 1×10^6 cells per mouse. These mice are implanted with a minipump, as above, which dispenses 4 mg/kg/day of the peptide or vehicle over a period of 14 or 21 days.

At termination of treatment, the animals are euthanized and the tumor marker probe CAT is assayed in regional lymph nodes, femurs, lungs, and brain.

In the mice treated with RTLPPD, but not with vehicle or control cyclic peptides, the number and size of metastatic foci is markedly inhibited. RTLPPD and its derivatives to which ^{131}I is conjugated (either 1 or 2 I atoms per molecule of cyclic peptide) are effective radiotherapeutics and are found to be at least two-fold more potent than their unconjugated analogues. These results indicate that these uPAR-targeting cyclic peptide derivatives interfere with the metastatic process.

EXAMPLE XXI

Binding of Å36 to uPAR-Bearing Cells and to Soluble uPAR ("suPAR")

Whole Cell Binding Studies

HeLa cells (about 5×10^4 /well) were plated in medium MEM with Earle's salts/10% FBS + antibiotics) in 24-well plates, then incubated in a humid 5% CO_2 atmosphere until the cells reached 70% confluence. Catalytically inactivated high molecular weight uPA (DFP-uPA) labeled with radioactive ^{125}I (specific activity $\sim 250,000$ cpm/mg) served as the uPAR label. Plates in which the cells were incubated were chilled on ice and the cells were washed twice (5 minutes each) with cold PBS/ 0.05% Tween-80. DFP-uPA and Å36 were serially diluted in cold PBS/ 0.1 % BSA/ 0.01% Tween-80 and added to each well to a final volume of 0.3mL 10 minutes prior to the addition of [^{125}I]DFP-uPA. Each well then received 9500 cpm of [^{125}I]DFP-uPA at a final concentration of 0.2 nM). The plates were incubated at 4°C for 2 hrs, after which the cells are washed 3x (5 minutes each) with cold PBS/ 0.05% Tween-80. Cells were lysed by addition of NaOH (1N) 0.5 mL/well for 5 minutes at room temperature or until all the cells in each well were lysed by microscopic examination. The contents of each well were aspirated, and the total counts in each well were determined using a gamma counter. Each compound was tested in triplicate and the results were expressed as a percentage of the total radioactivity measured in wells containing [^{125}I]DFP-uPA alone, which is taken to represent maximum (100 %) binding.

The inhibition of binding of [125 I]DFP-uPA to uPAR is dose-related, so that the IC₅₀ value (concentration of test compound that produced a 50% inhibition of binding) falls in the linear part of the curve and is easily determined.

Results

Å36 had a K_d of 30 nM for suPAR when competing with immobilized scuPA for binding to HeLa cells. Clearly, this value was lower than that determined in BIAcor studies reported below, which is not unusual for a receptor antagonist.

BIAcor Studies

Surface Plasmon Resonance

These studies were performed using soluble uPAR ("suPAR"). Binding kinetics of suPAR in the presence and absence of Å36 was measured using a BIA 3000 optical Biosensor (Biacore, AB, Sweden). (Myszka, 1997). This method detects binding interactions in real time by measuring changes in the refractive index (RI) at a biospecific surface, and enables calculation of association and dissociation rate constants.

For these studies, recombinant scuPA and recombinant suPAR were coupled to CM5-research grade sensor chip flow cells (Biacore, AB, Sweden) via standard amine coupling procedures [Johnsson, 1995] using N-hydroxysuccinimide/N-ethyl-N'-[3-(dimethylamino) propyl] carbodiimide hydrochloride (Pierce, Rockford, IL) at a level of 1000RU each. Sensor surfaces were coated with ligands (10 µg/mL) in 10mM NaAc buffer, pH=5.0. Following immobilization, unreacted groups were blocked with 1M ethanolamine, pH=8.5. Binding buffer was PBS, pH 7.4, 0.005% TWEEN-20. Binding of suPAR (\pm Å36) was measured at 25°C at a flow rate of 100 µL/min for 1 minutes, with 2 minutes of dissociation examined. The bulk shift due to changes in RI was measured using the suPAR surface, and was subtracted from the binding signal at each condition to correct for non-specific signals. Surfaces were regenerated with 2 x 30 sec pulses of 1M NaCl, pH=3.3, followed by an injection of binding buffer for 1 minute to remove this high salt solution. All injections were performed in a random fashion using the RANDOM command in the automated method. The ability of Å36 to inhibit the binding of scuPA to immobilized suPAR was evaluated at 100, 25, 10, 2.5, 1 and 0.5 nM Å36 in the presence of 10 nM scuPA. The total amount of

scuPA bound was plotted against the concentration of Å36 to establish an IC₅₀. Data were fit using a 1:1 Langmuir reaction mechanism using BIA evaluation 3.0 software (Biacore, AB, Sweden). Dissociation and association rates were calculated separately to examine the effect of Å36 on the affinity of suPAR to scuPA.

5 Results

Å36 has a K_d of 4 nM for suPAR when competing with immobilized scuPA. In the same assay, scuPA had a K_d of 1.5 nM. Thus, in a purified system with only scuPA and suPAR, the K_d of Å36 is very similar to the that of the native ligand. Clearly, this value falls off in the HeLa cell-based system (above), which is not unusual for a receptor antagonist.

10 These results indicate that Å36 binds to uPAR as this peptide is derived from the N-terminal “growth factor domain” (GFD) of scuPA.

EXAMPLE XXII

Biological Activities of Å36 in the Inhibition of Cell Migration and Tumor Invasiveness

15 A. HUVEC cell migration

The ability of Å36 to inhibit endothelial cells migration was evaluated in a transwell migration assay as described above. Transwells (8.0 µm pore size) were coated with Type I Collagen (0.1 mgs/mL, 0.1 mL/transwell) by allowing the collagen solution to dry down on the filter overnight at room temperature in a laminar flow hood. HUVEC were resuspended in
20 M199 media containing 10% FBS and added (100,000 cells) to the upper chamber of a transwell. This same media was added to the lower chamber of the transwell and in some cases, bFGF (FGF-2, 10 ng/mL) was also added to the bottom chamber to stimulate migration. Å36 was added to the upper chamber. The transwells were incubated for 5 hours at 37°C in a humidified environment containing 5% CO₂. Cells remaining in the upper
25 chamber were removed by scraping and the migrated cells were fixed and stained using Giemsa. The migrated HUVECs were counted under high magnification (200x) and the average of 5 fields per transwell was obtained.

The results, shown in Figure 7, indicate that Å36 inhibited cell migration in a dose-related manner and is active in the 40 nM range.

B. Invasiveness of PC3MLN4 tumor cells

Effects of Å36 on the invasiveness of PC3MLN4 cells were tested as described above. Transwell polycarbonate filters (8.0 µm pore size) were coated with Matrigel® (100 µg/mL in PBS). Highly invasive prostate carcinoma cells (PC3MLN4, 200, 000 cells in serum free RPMI 1640) were added to the upper chamber of a transwell. Serum free media was also added to the lower chamber of the transwell and in some wells, hepatocyte growth factor (HGF, 40 ng/mL) was included in the lower chamber to stimulate invasion. The ability of Å36 to inhibit invasion was evaluated by adding the compound to the upper chamber with the tumor cells. The transwells were incubated at 37°C in a humidified environment containing 5% CO₂ for 48 hours. The upper chambers were then scraped to remove cells that did not invade and the filter was fixed and stained with Giemsa. Invaded cells were counted at high magnification (200x) and the average of ten fields per sample was obtained.

The results, shown in Figure 8, demonstrated that Å36 inhibited HGF-induced invasiveness by these tumor cells at concentrations of 100 and 500 nM.


The references cited above are all incorporated by reference herein in their entirety, whether specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A uPAR-targeting cyclic peptide compound of formula



wherein, each of X^1 through X^{11} is a D- or L-amino acid, and

X^1 is Val, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X^2 is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹, or Ala;

X^3 is Asn or Gln;

X^4 is Lys, Arg or His;

X^5 is Tyr, Trp, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X^6 is Phe, Tyr, Trp, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

X^7 is Ser, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X^8 is Asn, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X^9 is Ile, Leu, Val, NorVal or NorLeu;

X^{10} is His, Cys, HomoCys, Glu, Asp, GluR¹, AspR¹ or Ala;

X^{11} is Trp, Tyr, Phe, substituted Phe, di-substituted Phe, HomoPhe, β -(3-pyridyl)alanine, β -(2-thienyl)alanine, β -(1-naphthyl)alanine, or β -(2-naphthyl)alanine;

(i) the pK_a of each NH_2 group in a parent diamine $H_2N-R^2-NH_2$ of said R^1 group $-NH-R^2-NH_2$ is less than about 8.0, and

(ii) the pK_a of the NH_2 group in said R^1 group is less than about 8.0, and

2. The cyclic peptide compound of claim 1, wherein R^2 is:

- (a) symmetric or non-symmetric with respect to the placement of the amino groups upon it;
- (b) noncyclic or cyclic, which, when cyclic,
 - (i) is heterocyclic, homocyclic, or polycyclic, wherein
 - when it is polycyclic the rings may be fused, unfused or a combination of both fused and unfused, and wherein various of said rings may be homocyclic, heterocyclic or a mixture of both
 - (ii) has the amine groups bonded to the cycle as direct substituents upon the cycle, spaced therefrom or both;
- (c) substituted with one or more substituents,
- (d) $-O-(CH_2)_x-O-$ wherein $10 \geq x \geq 2$, or
- (e) $-CH_2-CO-NH-(CH_2)_x-NH-CO-CH_2-$ wherein $10 \geq x \geq 2$.

4. The compound of claim 1 wherein the linear dimension between the C^α carbon of amino acid X¹ and the C^α carbon of amino acid X¹¹ is between about 5 and 10 Ångstrom units.

5. The compound of claim 4 wherein the linear dimension between the C^α carbon of amino acid X¹ and the C^α carbon of amino acid X¹¹ is between about 6 and 8 Ångstrom units.

6. The compound of claim 1, wherein L is a linker that, reading in the direction X¹-L-X¹¹, is selected from the group consisting of :

- L1 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CO-NH₂) -NH- ;
- L2 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂SH) -CO-NH₂) -NH- ;
- L3 -CO-CH (CH₂SH) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L4 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂CH₂SH) -CO-NH₂) -NH- ;
- L5 -CO-CH (CH₂CH₂SH) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L6 -CO-CH (CH₂CH₂COR¹) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L7 -CO-CH (CH₂COR¹) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L8 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂CH₂COR¹) -CO-NH₂) -NH- ;
- L9 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂COR¹) -CO-NH₂) -NH- ;
- L10 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-COR¹) -NH- ;
- L11 -CO-CH (CH₂CH₂COOH) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L12 -CO-CH (CH₂COOH) -NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CONH₂) -NH- ;
- L13 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂CH₂COOH) -CO-NH₂) -NH- ;
- L14 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH (CH₂COOH) -CO-NH₂) -NH- ; and
- L15 -CO-CH₂-NH-CO-CH₂-CH₂-CH (CO-NH-CH₂-CO-NH-R¹) -NH- ,

wherein R¹ in any of L6-L10 is a diamino group -NH-R²-NH₂ wherein R² is an organic residue, said diamino group having the following properties:

- (i) the pK_a of each NH₂ group in a parent diamine H₂N-R²-NH₂ of said R¹ group -NH-R²-NH₂ is less than about 8.0; and
- (ii) the pK_a of the NH₂ group in said -NH-R²-NH₂ is less than about 8.0.

and wherein R¹ in L15 is an organic residue.

7. The compound of claim 2, wherein L is a linker that, reading in the direction X¹-L-X¹¹, is selected from the group consisting of :

- L1 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CO-NH₂)-NH- ;
- L2 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂SH)-CO-NH₂)-NH- ;
- L3 -CO-CH(CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L4 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂SH)-CO-NH₂)-NH- ;
- L5 -CO-CH(CH₂CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L6 -CO-CH(CH₂CH₂COR¹)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L7 -CO-CH(CH₂COR¹)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L8 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂COR¹)-CO-NH₂)-NH- ;
- L9 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂COR¹)-CO-NH₂)-NH- ;
- L10 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-COR¹)-NH- ;
- L11 -CO-CH(CH₂CH₂COOH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L12 -CO-CH(CH₂COOH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L13 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂COOH)-CO-NH₂)-NH- ;
- L14 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂COOH)-CO-NH₂)-NH- ; and
- L15 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CO-NH-R¹)-NH- ,

wherein R¹ in any of L6-L10 is a diamino group -NH-R²-NH₂ wherein R² is an organic residue, said diamino group having the following properties:

- (i) the pK_a of each NH₂ group in a parent diamine H₂N-R²-NH₂ of said R¹ group -NH-R²-NH₂ is less than about 8.0; and
- (ii) the pK_a of the NH₂ group in said -NH-R²-NH₂ is less than about 8.0.

and wherein R¹ in L15 is an organic residue.

8. The compound of claim 3, wherein L is a linker that, reading in the direction X¹-L-X¹¹, is selected from the group consisting of:

- L1 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CO-NH₂)-NH- ;
- L2 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂SH)-CO-NH₂)-NH- ;
- L3 -CO-CH(CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L4 -CO-CH₂-NH-CO-CH₂-CH₂-CH(CO-NH-CH(CH₂CH₂SH)-CO-NH₂)-NH- ;
- L5 -CO-CH(CH₂CH₂SH)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;
- L6 -CO-CH(CH₂CH₂COR¹)-NH-CO-CH₂-CH₂-CH(CO-NH-CH₂-CONH₂)-NH- ;

- L7 $-\text{CO}-\text{CH}(\text{CH}_2\text{COR}^1)-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}_2-\text{CONH}_2)-\text{NH}-$;
- L8 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}(\text{CH}_2\text{CH}_2\text{COR}^1)-\text{CO}-\text{NH}_2)-\text{NH}-$;
- L9 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}(\text{CH}_2\text{COR}^1)-\text{CO}-\text{NH}_2)-\text{NH}-$;
- L10 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}_2-\text{COR}^1)-\text{NH}-$;
- L11 $-\text{CO}-\text{CH}(\text{CH}_2\text{CH}_2\text{COOH})-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}_2-\text{CONH}_2)-\text{NH}-$;
- L12 $-\text{CO}-\text{CH}(\text{CH}_2\text{COOH})-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}_2-\text{CONH}_2)-\text{NH}-$;
- L13 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}(\text{CH}_2\text{CH}_2\text{COOH})-\text{CO}-\text{NH}_2)-\text{NH}-$;
- L14 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}(\text{CH}_2\text{COOH})-\text{CO}-\text{NH}_2)-\text{NH}-$; and
- L15 $-\text{CO}-\text{CH}_2-\text{NH}-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CO}-\text{NH}-\text{CH}_2-\text{CO}-\text{NH}-\text{R}^1)-\text{NH}-$,

wherein R^1 in any of L6-L10 is a diamino group $-\text{NH}-\text{R}^2-\text{NH}_2$ wherein R^2 is an organic residue, said diamino group having the following properties:

- (i) the pK_a of each NH_2 group in a parent diamine $\text{H}_2\text{N}-\text{R}^2-\text{NH}_2$ of said R^1 group $-\text{NH}-\text{R}^2-\text{NH}_2$ is less than about 8.0; and
- (ii) the pK_a of the NH_2 group in said $-\text{NH}-\text{R}^2-\text{NH}_2$ is less than about 8.0.

and wherein R^1 in L15 is an organic residue.

9. The cyclic peptide compound of claim 6, 7 or 8, wherein R^2 in any of L6-L10 is:
 - (a) symmetric or non-symmetric with respect to the placement of the amino groups upon it;
 - (b) noncyclic or cyclic, which, when cyclic,
 - (i) is heterocyclic, homocyclic, or polycyclic, wherein

-when it is polycyclic the rings may be fused, unfused or a combination of both fused and unfused, and wherein various of said rings may be homocyclic, heterocyclic or a mixture of both
 - (ii) has the amine groups bonded to the cycle as direct substituents upon the cycle, spaced therefrom or both;
 - (c) substituted with one or more substituents;
 - (d) $-\text{O}-(\text{CH}_2)_x-\text{O}-$ wherein $10 \geq x \geq 2$; or
 - (e) $-\text{CH}_2-\text{CO}-\text{NH}-(\text{CH}_2)_x-\text{NH}-\text{CO}-\text{CH}_2-$ wherein $10 \geq x \geq 2$.

- DC052063

18. The compound of claim 1, 2 or 3 wherein, when said linker L includes a Cys, HomoCys, Glu, Asp, GluR¹ or AspR¹ amino acid residue, said amino acid residue is a D- or L-enantiomer.

19. The compound of claim 1, 2, 3, 6, 7 or 8, having an IC₅₀ value in a competitive binding assay to uPA receptor *in vitro* of less than about 10⁻⁵ molar

20. The compound of claim 19 having an IC₅₀ value in a competitive binding assay to uPA receptor *in vitro* of less than about 10⁻⁶ molar.

21. The compound of claim 20 having an IC₅₀ value less than about 10⁻⁷ molar.

22. A uPAR-targeting pharmaceutical composition comprising:

- (a) the cyclic peptide compound of any of claims 1, 2, 3, 6, 7 and 8; and
- (b) a pharmaceutically acceptable carrier.

23. The pharmaceutical composition of claim 22 in a form suitable for injection.

24. A uPAR-targeting therapeutic composition comprising :

- (a) an effective amount of the compound of any of claims 1, 2, 3, 6, 7, 8 bound directly or indirectly a therapeutically active moiety; and
- (b) a therapeutically acceptable carrier.

25. The composition of claim 24 in a form suitable for injection.

26. The composition of claim 24, wherein said moiety is a radionuclide.

27. The composition of claim 26, wherein said radionuclide is selected from the group consisting of ¹²⁵I, ¹³¹I, ⁹⁰Y, ⁶⁷Cu, ²¹⁷Bi, ²¹¹At, ²¹²Pb, ⁴⁷Sc, and ¹⁰⁹Pd.

28. A method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an effective amount of the compound of any of claims 1, 2, 3, 6, 7 or 8.

29. A method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an effective amount of the composition of claim 22.

30. A method for inhibiting cell migration, cell invasion, cell proliferation or angiogenesis, or for inducing apoptosis, comprising contacting cells associated with undesired cell migration, invasion, proliferation or angiogenesis with an effective amount of the composition of claim 24.

31. A method for inhibiting the invasiveness of tumor cells comprising contacting said cells with an effective amount of the compound of any of claims 1, 2, 3, 6, 7 or 8.

32. A method for inhibiting the invasiveness of tumor cells comprising contacting said cells with an effective amount of the composition of claim 22.

33. A method for inhibiting the invasiveness of tumor cells comprising contacting said cells with an effective amount of the composition of claim 24.

34. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 22.

35. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 23.

36. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 24.

37. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 25.

38. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 26.

39. A method for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 27.

40. A method according to claim 34-39, wherein said disease or condition is primary growth of a solid tumor, leukemia or lymphoma; tumor invasion, metastasis or growth of tumor metastases; benign hyperplasia; atherosclerosis; myocardial angiogenesis; post-balloon angioplasty vascular restenosis; neointima formation following vascular trauma; vascular graft restenosis; coronary collateral formation; deep venous thrombosis; ischemic limb angiogenesis; telangiectasia; pyogenic granuloma; corneal disease; rubeosis; neovascular glaucoma; diabetic and other retinopathy; retrolental fibroplasia; diabetic neovascularization; macular degeneration; endometriosis; arthritis; fibrosis associated with a chronic inflammatory condition, traumatic spinal cord injury including ischemia, scarring or fibrosis; lung fibrosis, chemotherapy-induced fibrosis; wound healing with scarring and fibrosis; peptic ulcers; a bone fracture; keloids; or a disorder of vasculogenesis, hematopoiesis, ovulation, menstruation, pregnancy or placentation associated with pathogenic cell invasion or with angiogenesis.

41. A method according to claim 40, wherein said disease is tumor growth, invasion or metastasis.

42. A diagnostically useful uPAR-targeting ligand composition comprising:

- (a) the compound of any of claims 1, 2, 3, 6, 7, 8 which is diagnostically labeled;
- (b) a diagnostically acceptable carrier.

- thereby isolating said uPAR.

- (a) contacting said cell mixture with the uPAR-binding ligand compound of any of claims 1, 2,, 3, 6, 7, 8;
- (b) allowing any uPAR-expressing cell to bind to said compound;
- (c) separating cells bound to said ligand from unbound cells; and
- (d) removing said bound cells from said ligand,

- (a) contacting said cell mixture with the affinity ligand of claim 49;
- (b) allowing any uPAR-expressing cell to bind to said ligand;
- (c) removing unbound cells from said ligand and from said bound cells; and
- (d) releasing said bound cells,

92

ABSTRACT

uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the α -carbons of the first and the eleventh amino acids is between about 4 and 12 Ångstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are useful for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.

Fig. 1




Fig. 2




Fig. 3

Figure 1 is a line graph showing the binding of Biotin-RTLPPD and -RTL-PPD to the BSA-NTS conjugate. The Y-axis represents % Bound (0 to 120), and the X-axis represents Concentration (nM) on a logarithmic scale (0.1 to 10,000). Biotin-RTLPPD (open circles, solid line) shows high binding affinity, while -RTL-PPD (open squares, dashed line) shows lower binding affinity.

Concentration (nM)	% Bound (Biotin-RTLPPD)	% Bound (-RTL-PPD)
1	99	69
10	99	30
50	95	20
100	84	16
500	38	11

Fig. 4

RTLPPD (μM)	Cells Invaded (5 Fields)
0	335
1	135
5	160

Fig. 5

UNSTIMULATED HMVEC

STIMULATED (bFGF + VEGF) HMVEC







Fig. 6

005077-1E240260

Fig. 7

**HUVEC CELL MIGRATION IS INHIBITED BY A36
IN THE PRESENCE OF 10% FBS**






Fig. 8

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION
English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled, CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR the specification of which

- ☒ is attached hereto.
- ☐ was filed on _____ as Serial No. _____
and was amended on _____ (if applicable)
- ☐ was described and claimed in PCT International Application No. _____,
filed on _____ and as amended under PCT Article 19 on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PROVISIONAL APPLICATION NUMBER	FILING DATE
--------------------------------	-------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>09/181,816</u> (Application Serial No.)	<u>October 29, 1998</u> (Filing Date)	<u>Pending</u> (Status)
<u>09/285,783</u> (Application Serial No.)	<u>April 5, 1999</u> (Filing Date)	<u>Pending</u> (Status)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

English Language Declaration

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald P. Kananen, Reg. No. 24,104; Shmuel Livnat, Reg. No. 33,949; Ralph T. Rader, Reg. No. 28,772; Michael D. Fishman, Reg. No. 31,951, Richard D. Grauer, Reg. No. 22,388; Joseph V. Coppola, Sr., Reg. No. 33,373; Michael B. Stewart, Reg. No. 36,018; Christopher M. Tanner, Reg. No. 41,518; David K. Benson, Reg. No. 42,314; Robert S. Green, Reg. No. 41,800.

Send Correspondence to:

Direct telephone calls to:

Shmuel Livnat
RADER, FISHMAN & GRAUER
1233 20th Street, N.W., Suite 501
Washington, D.C. 20036

Shmuel Livnat
(202) 955-3750

Full name of sole or first inventor Terence R. JONES	
Inventor's signature	Date
Residence: San Diego, CA 92109	
Citizenship United Kingdom	
Post Office Address 1962 Missouri Street, San Diego, California 92109	
Full name of second joint inventor David N. Haney	
Second Inventor's signature	Date
Residence: Mercer Island, Washington 98040	
Citizenship U.S.A.	
Post Office Address 4212 93 rd Avenue SE, Mercer Island, Washington 98040	
Full name of sole or third inventor Janos VARGA	
Third Inventor's signature	Date
Residence: Napa, California 94558	
Citizenship U.S.A.	
Post Office Address Laurel Lane, Napa, California 94558	

(Supply similar information and signature for subsequent joint inventors.)